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ABSTRACT 
 
 
DEVELOPMENT OF ABUSE DETERRENT FORMULATIONS USING 
                                                            HOT MELT EXTRUSION 
 
  PAVAN KUMAR NUKALA 
 
 
 
 
In recent years prescription drug diversion, misuse, abuse represent a growing problem for the 
United States. Oral ingestion, snorting, injection are most commonly employed routes of 
abuse. To circumvent this problem hot melt extrusion (HME) was employed to prepare 
abuse deterrent formulation (ADF). 
Abuse Deterrent Immediate Release Egg-Shaped Tablet Using 3D Printing Technology: 
Quality by Design to Optimize Drug Release and Extraction. 
In current work, we developed egg-shaped tablet (egglet) using fused deposition 
modeling (FDM) 3D printing. Drug-loaded polymeric filaments (1.5 mm) were prepared 
using HME followed by printing into egglets of different sizes and infill densities. Based 
on printability, crush resistance polyvinyl alcohol (PVA) was used further. Later, egglets 
were evaluated for abuse deterrence properties based on USFDA guidance. A 
multifactorial design was used to optimize solvent extraction, drug release. Extreme 
hardness (> 500 N), large particle size (> 1 mm) on mechanical manipulation 
ii 
established snorting deterring property while <20% drug extraction in 5 min (% Sext) 
demonstrated deterrence for injection abuse. Quality target product profile D85 < 30 min, 
% Sext < 20 was achieved with egglets of 6 mm diameter, 45% infill density, 15% w/w drug 
loading. 
Development of Multi-dose Oral Abuse Deterrent Formulation of Loperamide 
Using Hot melt extrusion. 
Loperamide, an over the counter anti-diarrheal drug, also referred as "poor man's 
methadone". Abusers consume more than 30 tablets to achieve euphoria and to combat 
opioid withdrawal. But supratherapeutic doses causes respiratory depression, cardiac 
dysrhythmia, mortality. Aim is designing a tablet which can immediate release 
loperamide in diarrheic patients (single tablet) while stops release in case of intentional 
multi-dose ingestion. Loperamide was molecularly dispersed into gastric soluble cationic 
polymers - Eudragit® EPO, Kollicoat® Smartseal 100P using HME to obtain filament. 
Filaments were milled and compressed into tablets ((Eudragit® EPO (SJU1) and 
Kollicoat® Smartseal (SJU2)) with optimized amount of L-arginine. Dissolution in 
250 mL of Fasted state simulated gastric fluid (FaSSGF) revealed that single tablet of 
Imodium® (marketed formulation) and SJU1 showed >85% of release in 15 min. In 
iii 
multi-unit dissolution (15 tablets), Imodium® exhibited >90% release but SJU tablets 
showed <5% of release thus demonstrating its ability to deter multi-dose oral abuse. 
iv 
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1. Introduction 
 
 
            1.1. Opioid epidemic 
 
 
Pain is an important condition that requires medical attention. Pain can be either 
chronic or acute. Generally non-steroidal anti-inflammatory (NSAID) and opioid drugs 
are used to treat or reduce pain. NSAID is responsible for blocking the function of the 
enzyme cyclooxygenase which leads to prostaglandins synthesis. However, opioid 
analgesics work as an agonist on opioid receptors located in central and peripheral 
nervous system. Based on the differences in their mechanisms of action, opioid 
analgesics are more effective than NSAID in treating most severe cases of pain 
(Rahman et al., 2016). Commonly used opioid drugs include morphine, codeine, 
oxymorphone, oxycodone and heroin, which can be administered by various routes: 
oral, rectal, sublingual, transdermal, subcutaneous, intramuscular, intravenous, or 
neuraxial (Maincent and Zhang, 2016; Rahman et al., 2017). In the past few years, 
prescription drug abuse has gained a lot of attention and is a rapidly growing concern 
in United States (Rahman et al., 2016; Schaeffer, 2012). Abusers use various 
paraphernalia for physical manipulation of opioid drugs as shown in Fig. 1. (Park and 
Otte, 2019). Prescription opioids are preferred amongst abusers. The United States 
Food and Drug Administration (USFDA) defines abuse as an intentional and 
2  
nontherapeutic use of drug product or any substance to achieve a physiological or 
psychological effect (Administration, 2017; Food and Administration, 2015). Misuse 
refers to inappropriate intentional therapeutic use of a drug substance specifically 
excluding abuse (Administration, 2017; Food and Administration, 2015; Katz et al., 
2007). In 2016, 433,000 deaths were recorded due to lawful and unlawful use of 
opioids. The overall medical and productivity loss costs occurred with prescription 
opioid analgesic misuse, abuse, and deviation are accounted to be $78.5 billion 
annually (Cohen et al., 2018). Opioid drugs and their derivative products are potential 
candidates for misuse and abuse due to euphoric effects from their use. These drugs, 
being easily available to the target population, have been largely misused or abused via 
physical or chemical manipulation to attain elevated drug concentrations in the body 
(Maddineni et al., 2014). 
3  
 
 
 
 
 
 
 
 
 
  
               Fig. 1. Various Paraphernalia used for Physical manipulation.  
                                      (Adapted from Park and Otte, 2019) 
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1.2. Various routes of abuse 
 
 
Most approved opioid drugs currently on the market are formulated for oral 
route of administration (e.g., Tablets, capsules, solutions, etc.) (Xu et al., 2016). The 
undesired effects of opioid misuse may vary depending on the preferred route of 
administration (Maddineni et al., 2014). Opioid drugs can be abused through ingestion 
(chewing or oral/ intake exceeding the recommended dose), inhalation (snorting, 
smoking or inhaling) and injection (intravenous, intramuscular, or subcutaneous 
administration) to attain “high effect” (Meruva and Donovan, 2019, 2020; Pergolizzi 
Jr et al., 2018). Often, an abuser will crush or grind the prescription opioid into a ground 
powder or fine particles followed by nasal insufflation, or by dissolving it in solvents 
such as ethanol and water for injection as shown in Fig. 2. (Rahman et al., 2017). 
Nonmedical use of prescription opioids through nonoral route has been associated with 
several adverse effects from intranasal (IN) abuse and can lead to the destruction of the 
nasal and palatal tissue. Abuse through intravenous (IV) routes can cause viral 
infections due to needle sharing and reuse of same needle. There has been a rise in 
abuse of extended release (ER) dosage forms due to fact that there is a higher amount 
of drug per unit dosage form. While immediate formulations (IR) of the same opioid 
has smaller dose of drug per unit dosage form (Maddineni et al., 2014; Xu et al., 
5  
2016). Differences in pharmacokinetic profile are reported from tablet crushing, and 
these variations range from moderate changes to complete profile change (Maincent 
and Zhang, 2016; Schaeffer, 2012). Overall, the oral route is the preferred choice, 
followed by snorting and injection. Yet, the highest mortality and severe morbidity 
rates are caused by parenteral and nasal routes (Xu et al., 2016). 
6  
 
 
 
 
Fig. 2. Various routs of Abuse. 
(Adapted from Rahman et al., 2017)
Oral 
Routes of 
 Snorting 
(Nasal 
Insufflation) 
Injection 
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1.3. Emergence of Abuse deterrent formulations 
 
 
To fight prescription opioid abuse, pharmaceutical manufacturers and the 
USFDA are confronting this issue by coming up with a novel concept of abuse deterrent 
formulations (ADFs). The USFDA and CDER (Center for drug evaluation and 
research) has initially issued its guidance to industry on “Abuse-Deterrent Opioids- 
Evaluation and Labeling in April 2015. Later in November 2017, “General Principles 
for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products” 
guidance to industry has been released by the USFDA and CDER. To deter the opioid 
abuse, various strategies including physical/chemical barriers, agonist/antagonist’s 
combinations, aversion, new routes of delivery system, new molecular entities and 
prodrugs have been investigated (Administration, 2017; Food and Administration, 
2015). But essentially, ADFs will not provide resistance to abuse. The USFDA refers 
to these formulations designed to deter the abuse of prescription opioids as “abuse 
deterrent” rather than “tamper resistant”. Formulations with increased resistance to 
mechanical manipulation are demonstrated to have the potential to deter certain types 
of illicit use because they cannot be easily crushed in to forms that are readily snorted 
or injected. Currently, there are seven opioid formulations that have been labeled as 
abuse deterrent by the USFDA as shown in Table 1(Peacock et al., 2019). Many other 
8  
formulations and technologies with progressively improved abuse deterrence 
properties are currently being evaluated (Administration, 2017; Alexander et al., 2014; 
Boyce et al., 2018a; Cohen et al., 2018; Food and Administration, 2015; Khan and 
Gharibo, 2010; Marnoor, 2016; Schaeffer, 2012). The USFDA has outlined 4 
categories (Table 2) to evaluate abuse deterrent properties (Food and Administration, 
2015). 
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Table 1. Various abuse deterrent products with its marketing status 
                          (Adapted from Peacock et al., 2019) 
 
 
 
Product Active 
 
Ingredient/Release 
Marketing status 
Oxycontin Oxycodone HCl/ER Prescription 
Embeda Morphine Sulfate; 
 
Naltrexone HCl/ER 
Prescription 
Hysingla ER HydrocodoneBitartrate/ER Prescription 
MorphaBond ER Morphine Sulfate/ER Prescription 
Xtampza ER Oxycodone/ER Prescription 
Arymo ER Morphine Sulfate/ER Prescription 
RoxyBond Oxycodone HCl/IR Discontinued 
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Table 2. Categories for evaluation of abuse deterrent properties 
                                                      (Adapted from Food and Administration, 2015) 
 
Category 1: Laboratory-based in 
vitro manipulation and extraction 
studies 
To evaluate with which abuse deterrent 
properties can be defeated or 
compromised. 
Category 2: Pharmacokinetic 
studies 
Understand the in vivo properties of the 
formulation by comparing 
pharmacokinetic profiles of manipulate 
and intact formulations. 
Category 3: Clinical abuse 
potential studies 
Applying clinical abuse potential studies 
to assess the potentially abuse deterrent 
properties. 
Category 4: Post marketing 
 
studies 
Understand the in vivo properties of the 
 
formulation by comparing PK profiles. 
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1.4. Impact of Abuse deterrent formulations on progressive shift to abuse of IR 
opioids 
Economic modeling analyses indicate that ADF opioids have the potential to 
substantially reduce the incidence of opioid abuse in prescribed chronic pain patients 
relative to non-ADF opioids, but at significantly lower cost to the health care system 
(Severtson et al., 2016). ADFs are less attractive to abusers than available non ADF 
products because these formulations by definition are designed to defeat the abuser’s 
manipulation there by making it less rewarding and more challenging (Katz et al., 
2011). The rate of intentional abuse, based on US Poison Center Program data, has 
been reduced by approximately 75% since the past 5-year period after the approval of 
an ADF of oxycodone (Severtson et al., 2016; Wening et al., 2017). After the 
introduction of ADFs for ER opioids, there is a substantial increase in abuse of IR 
opioids was observed due to its availability and ease of abuse compared to ER 
formulations (Cicero et al., 2017; Iwanicki et al., 2016). Additionally, in between 2009 
-2015 IR opioids were prescribed in higher rate of 12-16 times compared to ER opioids 
(Iwanicki et al., 2016). Numerous reports indicate that intentional abuse of IR opioids 
was about 5 folds higher on comparison with ER opioids (Cicero et al., 2017). 
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Chewing and snorting are the most common way to abuse an IR product (Beaumont et 
al., 2018; Wening et al., 2017). 
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1.5. Abuse of Novel psycho active substances 
 
 
Due to the limited availability of prescription opioids and emergence of ADF’s 
by the USFDA, the modern-day abusers have been shifting towards novel psycho active 
substances (NPS). A range of prescription (e.g. Pregabalin, Gabapentin etc.) and over 
the counter (OTC) drugs (e.g. Loperamide, Dextromethorphan etc.) were categorized 
as NPS’s due to their scope of abuse from large doses, which yields intense 
psychoactive action and cannot be diagnosed in drug screening. A perfect example is 
an OTC anti-diarrheal drug, loperamide. This OTC medication is gaining popularity as 
a drug of abuse for attaining euphoria and for amelioration of opioid withdrawal 
symptoms. Due to its ease of availability and very low price, loperamide, is gaining 
interest among many opioid abusers. Numerous reports indicate loperamide to be 
alternative for opioids. Based on the USFDA report, loperamide abuse and misuse 
initiates, especially at doses of 60 mg (around 30 tablets). 
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1.6. Literature review 
 
 
Literature published in the area of abuse deterrent technology is limited, 
majority of available literature is through patents. However, recently research on 
ADF’s has been emerging after the issue of the USFDA’s guidance to industry. In a 
recent study by Rahman et al., authors investigated the effect of excipients and curing 
process on Polyox™ (Polyethylene oxide) based abuse deterrent formulation prepared 
using direct compression. In addition, they have concluded that crush resistance was 
mainly imparted by Polyox™. Addition of excipients > 50% other than Polyox™ was 
found to affect the hardness, drug extraction in solvents for abuse (Rahman et al., 2017). 
Inclusion of high viscosity grade polymers resulted in reduced resistance to crushing 
and increased resistance to solvent extraction by forming gel. In study by Maddineni et 
al., the authors developed an abuse deterrent dosage form from Polyethylene oxide 
(Polyox WSR 301) based matrix using hot melt extrusion followed by pelletizing the 
extrudates. However, their primary objective was to utilize design of experiments to 
optimize the formulation in terms of percentage of drug extracted in water and alcohol 
(Maddineni et al., 2014). In addition, their formulation design does not include non-
Polyethylene oxide matrix and rationale for selecting formulation does not involve 
immediate release of drug. Wening et al., developed immediate release 
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ADF using hot melt extrusion technology (Wening et al., 2017). However, their 
rationale for formulation design did not utilize DOE. But their primary objective was 
based on a clinical study for comparison of vivo pharmacokinetic profile of IR ADF 
with marketed IR product of same opioid. Boyce et al., studied the nasal drug release 
manipulated Polyethylene oxide-based drug product using an in vitro vertical diffusion 
cell after nasal insufflation (Boyce et al., 2018b). Based on the available literature till 
now, there is no previous report of demonstrating the development of a formulation 
addressing the issue of multi dose oral abuse of loperamide hydrochloride (LPH). A 
recent US patent by Shah N. H. and co-workers demonstrated an application of multi- 
particulate system with functionality coatings in limiting overdose and abuse of an 
opioid drugs. Investigators have developed an enteric coated crush resistant granules 
of oxycodone HCl and other opioids (Shah et al., 2019). Most of the ADF formulations 
developed using conventional methods possess many steps of processing like 
granulation, milling, punching, coating, curing etc. This requires higher cost and 
additional time for development. 
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1.7. Hot melt extrusion 
 
 
Hot melt extrusion (HME) is a novel and viable method adopted by 
pharmaceutical industry for enhancing the bioavailability of poorly soluble drugs 
through formation of molecular dispersions (Repka et al., 2008). In HME, initially 
crystalline API and polymer were physically blended, later processed through different 
heating zones as shown in Fig. 3 (Kolter et al., 2012). Within those heating zones the 
API polymeric mixture gets mixed, melted and exits as a filament. This process majorly 
yields a solid dispersion, in majority of the cases it forms a molecular dispersion. With 
HME, the drug is dissolved usually in amorphous form within polymer at higher 
temperatures (above glass transition temperature of polymer) and high shear rate 
through twin screw extruder (Censi et al., 2018). HME is very efficient in cutting down 
the time and cost involved in development. Additionally, HME was recently found to 
be very viable in development of ADF’s (Maddineni et al., 2014; Wening et al., 2017). 
In current study HME was utilized in development of ADF by means of physical and 
chemical approaches. 
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Fig. 3. Hot melt extrusion is an efficient processing method for obtaining solid 
dispersions. (Adapted from Kolter et al., 2012)
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            2. Purpose of Study 
 
 
The USFDA is encouraging the development of prescription opioids with 
ADF’s to help combat the opioid crisis. ADF’s are designed to defeat the abuser’s 
manipulation there by making it less rewarding and more challenging. HME is a novel 
and viable method adopted by pharmaceutical industry for enhancing the 
bioavailability of poorly soluble drugs through formation of molecular dispersions. 
HME, in conjunction with suitable polymers, has been demonstrated as a viable 
approach to develop dosage form with potential abuse deterrent properties. Fig. 4. 
Summarizes the application of HME in preparation of ADF’s. 
Therefore, the purpose of present research is focused on developing 
 
 
a. An immediate release ADF and evaluating based on USFDA guidance for abuse 
deterrence. 
b. An abuse deterrent formulation for deterring multi dose oral abuse of Loperamide 
Hydrochloride. 
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Fig. 4. Application of Hot melt extrusion in preparation of Abuse deterrent 
formulations. 
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           3. Research Objectives 
 
 
I) There are no previous reports or patent demonstrating application of 3D printing in 
the preparation of abuse deterrent formulation involving HME. 
Specific Objectives include: 
 
 
1. To fabricate an immediate release ADF with an ability to deter abuse through 
crushing, snorting, and physical manipulation. 
2. Optimizing the drug release and extraction in solvents using quality by design. To 
achieve this aim, we explored FDM 3D printing technology to prepare an egg-shaped 
tablet (egglet). 
The hypothesis behind selecting the egg-shaped template for printing was to 
resemble the hard-outer surface of an egg. The hard-outer shell deters abusers from 
tampering and significantly reduces the drug extraction in commonly available 
solvents. Further, formation of comparatively large particles up on high-pressure 
grounding making it resistant towards snorting. 
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II) There is no previous report of demonstrating the development of a formulation 
addressing the issue of multi dose oral abuse of Loperamide HCl through HME. This 
is the very first work demonstrating development of abuse deterrent loperamide 
hydrochloride (LPH) tablets through hot melt extrusion of gastric soluble polymer 
Specific objectives include: 
 
 
1. Development of ADF of Loperamide HCl using HME to deter multi dose oral abuse. 
 
 
2. Identifying and optimizing the amount of free base required to raise the pH >5. 
 
 
3. Development of LPH tablet formulation (SJU tablet) prepared with gastric soluble 
polymer with fixed amount of base. 
4. Evaluation of single and multi-dose drug release of SJU tablets in bio-relevant media. 
 
 
We hypothesize that tablet containing (a) small amount of base and (b) LPH 
incorporated into pH sensitive polymer matrix can be helpful in curbing the LPH 
release when multiple tablets are consumed. We anticipate that on consumption of more 
than 15 tablets, the amount of base will be sufficient to raise the pH above 5 at which 
the polymer is insoluble. This increment in the pH will hinder the release of LPH from 
polymeric matrix. Herewith, this technology will be referred to as “SJU technology”. 
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4. Abuse Deterrent Immediate Release Egg-Shaped Tablet (Egglets) 
Using 3D Printing Technology: Quality by Design to Optimize Drug 
Release and Extraction 
             4.1. Introduction 
 
 
4.1.2. Drug (Metformin Hydrochloride) 
 
 
Due to limitations in procurement of opioid drugs for conducting research 
model drug was used in place of opioid drug. Metformin hydrochloride (MET) was 
chosen as a model drug due to its similarity in aqueous and alcohol solubility with 
opioid drug oxycodone hydrochloride. The drug properties of Metformin 
Hydrochloride and Oxycodone Hydrochloride were given in Table 3 and Table 4 (Ben- 
Hander et al., 2015; Kasim et al., 2004; Kortejärvi et al., 2014). There are literature 
reports indicating the use of MET as a model drug in research on developing ADF’s 
(Patel et al., 2018). 
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Table 3. Drug Information (Metformin Hydrochloride) 
 (Adapted from Ben- Hander et al., 2015; Kasim et al., 2004; Kortejärvi et al., 2014) 
 
 
 
Name Metformin Hydrochloride 
Chemical Name 1,1-Dimethylbiguanide hydrochloride 
Molecular formula C4H12ClN5 
Molecular weight 162.52 g/mol 
Structure 
 
 
CAS No. 1115-70-4 
Description Hydrochloride salt of the biguanide metformin 
Melting point 223℃-226℃ 
Partition coefficient 0.15 
 
Solubility 
Freely soluble in water 100 g/L and slightly soluble in 
 
alcohol 
BCS class Class III 
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Table 4. Drug Information (Oxycodone Hydrochloride) 
            (Adapted from Ben- Hander et al., 2015; Kasim et al., 2004; Kortejärvi et al., 2014) 
 
 
 
Name Oxycodone Hydrochloride 
 
Chemical Name 
4,5-epoxy-14-hydroxy-3-methoxy-17methylmorphinan- 
 
6-onehydrochloride 
Molecular formula C18H21NO4HCl 
Molecular weight 351.83 g/mol 
 
Structure 
 
 
CAS No. n/a 
Description Hydrochloride salt of Oxycodone 
Melting point 218℃-223℃ 
Partition coefficient 0.7 
 
Solubility 
Freely soluble in water 100 mg/mL and slightly soluble 
 
in alcohol 
BCS class Class I 
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4.1.3. 3D Printing 
 
 
3D printing is an additive manufacturing technology, in which layers of 
material are formed under computer control to develop 3D products (Okwuosa et al., 
2016). Attention has shifted towards 3D printing after the USFDA approval of 
‘Spritam®’, the first 3D-printed fast-dissolving tablet in late 2015, which utilizes 
powder adhering ZipDose™ technique in printing porous tablets (Nukala et al., 2019c; 
Skowyra et al., 2015). Recently, 3D printing technology has set the platform for patient- 
tailored dosage form where fabrication of dosage form can be carried out in desired 
dose, shape and size, which is difficult to achieve using traditional technologies (Fig. 
5.) (Jamróz et al., 2018). Various 3D printing technologies used for printing 
pharmaceuticals are binder jet printing, fused deposition modeling (FDM), semisolid 
extrusion, selective laser sintering and stereolithography (Yang et al., 2018). The 
properties of 3D-printed formulations vary with the technology opted for printing 
(Nukala et al., 2019c). 
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Fig. 5. Application of 3D Printing technology in printing in Various Shapes, sizes, 
models, Channeled printlets, various densities (infill).  
(Adapted from Jamróz et al., 2018)
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4.1.4. FDM 3D Printing 
 
 
FDM 3D printing is one of the emerging technologies in the field of 
pharmaceutics (Nukala et al., 2019c). In this technique, drug-loaded polymeric 
filaments (prepared using hot melt extrusion) are converted into solid dosage form of 
desired size and shape using a desktop 3D printer. Recently, the research utilizing FDM 
3D printing technology in fabrication of oral dosage forms is on the rise (Palekar et al., 
2019). FDM 3D printing would help in the fabrication of customized tablets with 
precision and ease compared with powder compaction, which is always done in bulk. 
In FDM 3D printing, initially digital 3D design is prepared using computer-aided 
design software. Later the design is imported to FDM 3D printer, next the filament is 
passed through the heated nozzle and extruded material is deposited on the build plate 
to prepare the desired object. The drug-loaded filaments are prepared using HME and 
used for FDM 3D printing as shown in (Fig. 6 and Fig. 7) (Zhang et al., 2017). 
Fabrication of dosage form can be done in various doses, shapes and sizes using the 
same equipment and drug loaded filaments (Skowyra et al., 2015). The drug release 
and rate can be modified by varying the size and shape of the dosage form, which can 
improve patient compliance (Okwuosa et al., 2016). 
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Fig. 6. Schematic Picture of desktop FDM 3D printer. 
              (Adapted from Zhang et al., 2017) 
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              Fig. 7. Coupling 3D printing with hot-melt extrusion to produce tablets. 
            (Adapted from Zhang et al., 2017) 
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4.1.5. Limitations of FDM 3D Printing 
 
 
The major limitations of existing FDM3D printing of pharmaceutical dosage 
form are high printing temperatures and printability of pharmaceutical polymers. In 
addition, polymer must be biocompatible, thermoplastic and heat stable for 
manufacturing using FDM 3D printing (Goyanes et al., 2015). The filaments should 
have tensile strength to be pushed by drive gear into the heated nozzle; the polymeric 
filaments of many pharmaceutical polymer do not exhibit tensile strength for 3D 
printing (Zhang et al., 2017). Moreover, polymer should have low glass transition 
temperature to conduct printing at lower temperature (Goole and Amighi, 2016). 
Pharmaceutical grade polymers explored for 3D printing are Eudragit® RL, 
Eudragit®RS, Eudragit®E, Eudragit®EPO, hydroxypropyl methylcellulose (HPMC), 
polylactic acid (PLA), polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) 
(Nukala et al., 2019c). 
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Fig. 8. Schematic diagram of proposed study (MET). 
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      4.2. Materials 
 
 
MET (>99%) was purchased from TCI America (Cambridge, MA). 
Parteck®MXP (polyvinyl alcohol) and Parteck®SI 150 (sorbitol) were generously 
gifted by EMD MilliporeSigma (Burlington, MA), and Klucel™ (hydroxypropyl 
cellulose) was obtained from Ashland (Covington, KY). Kollidon® VA 64 
(vinylpyrrolidone-vinyl acetate copolymer) and Affinisol™15LV were received as gift 
samples from BASF (Iselin, NJ) and Dow Chemical Company (Midland, MI), 
respectively. Hydrochloric acid, ethanol, acetone, and other solvents were purchased 
from Fisher Scientific (Pittsburgh, MA). All materials were used as received. 
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      4.3. Methods 
 
 
4.3.1. Analytical Method (UV Spectroscopy) 
 
Drug content analysis was carried out by UV spectrophotometer (BioTek 
Winooski, VT). Briefly accurately weighed drug was dissolved in distilled water to 
prepare a stock solution of 1 mg/mL. The solution was further diluted to prepare 
solutions of 10, 20, 30, 40, 50, and 100 μg/mL. The diluted solutions were analyzed at 
an absorbance wavelength of (λmax220 nm). The absorbance of each solution was 
measured in triplicate (n=3). The calibration curve of Y = 0.0522x + 0.0722 was 
acquired for metformin hydrochloride; R2 = 0.9999. 
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4.3.2. Hot melt extrusion of placebo polymers 
 
 
Various hydrophilic polymers were screened with an aim to identify a suitable 
polymeric matrix for preparation of an abuse deterrent/tamper-resistant formulation. 
Initial optimization of polymeric matrix was based on two criteria: printability and crush 
resistance. We have evaluated various polymeric filaments for their ease of printability 
and hardness required for crush resistance as per the USFDA guidance (>50 kg). Placebo 
polymeric (no drug loaded) filaments (1.5 mm diameter) of polyvinyl alcohol (PVA), 
hydroxypropyl cellulose (HPC) and Kollidon® VA64, Affinisol™ 15LV, and Kollicoat® 
IR with/without plasticizer were prepared by hot melt extrusion using twin screw 
extruder. In this study, instead of conventional-grade PVA, Parteck®MXP—a newly 
developed HME grade of PVA—was used (Palekar et al., 2019). A parallel 11-mm twin 
screw extruder (Process 11 Thermo Fisher Scientific, Waltham, MA) with eight electric 
heating zones with an L/D ratio of 40 was used for extrusion. Accurately weighed 
individual polymer and sorbitol were mixed in weight ratio of 9:1 using a mortar and 
pestle followed by thorough blending in a Turbula® mixer (Glen Mills, Clifton, NJ) for 
5 min to obtain homogenous blends. The screw design of extruder was designed to have 
three kneading zones along with conveying zones to impart proper mixing during 
extrusion. PVA blends were processed at 170°C 
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while other polymeric blends were extruded at 140–150°C. Blends were processed at a 
feed rate of 2 g/min through hopper to heated barrel followed by extrusion at a screw 
speed of 100 RPM. Output through 1.5 mm circular die converted molten mixture into 
suitable filaments which can be used as a feed stock to 3D printer. The temperature of 
die was maintained at 150°C during extrusion. Additionally, a conveyer belt was 
equipped next to die to cool and straighten the filaments exiting die. Filaments of 
desired length were cut from the conveyor belt and stored at room temperature in sealed 
bags prior to printing. 
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4.3.3. Hot melt extrusion of drug loaded filaments 
 
 
From the polymer screening, PVA and sorbitol mixture filaments possessed 
required criteria for 3D printing and crush resistance as per the USFDA guidance 
compared to other polymeric filaments and hence, PVA and sorbitol mixture was 
selected for further studies. In preparation of drug loaded filaments, accurately weighed 
MET, PVA and sorbitol were physically mixed in a mortar and pestle followed by 
thorough blending in a Turbula® mixer (Glen Mills, Clifton, NJ) for 5 minutes to obtain 
homogenous blends. Physical mixtures were prepared in a weight ratio of 8.5:1:0.5, 
8:1:1, 7.5:1:1.5 PVA: sorbitol: MET respectively, to obtain extrudates with 5% w/w, 
10% w/w,15% w/w drug loading (Table 5). Extrusion was carried out at 170o C with a 
screw speed of 100 RPM. Torque was analyzed during the extrusion. The obtained 
filaments were stored in sealed clear bags at room temperature. 
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Table 5. Composition of drug loaded mixtures processed through HME 
 
 
 
PVA (w/w %) Sorbitol (w/w %) Drug (w/w %) 
85 10 5 
80 10 10 
75 10 15 
PVA Polyvinyl alcohol 
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    4.3.4. Solid state characterization 
 
 
Characterization of the different components was carried out by differential 
scanning calorimetry (DSC) and x-ray powder diffraction (XRPD). 
4.3.4.1. Differential scanning calorimetry 
 
 
Differential scanning calorimetry (DSC) thermograms of pure excipients, drug, 
and crushed filament were obtained using a Q200 modulated DSC instrument (TA 
instruments, New Castle, Delaware). Accurately, weighed samples (5 mg) were 
hermetically sealed in an aluminum pan. The samples were equilibrated at 25°C and 
then heated from 25 to 250°C at a ramp of 2.5°C/min. Analysis was performed using a 
Q2000 analysis software provided by TA. 
 
 
4.3.4.2. X-ray powder diffraction 
 
 
X-ray powder diffraction (XRPD) of pure excipients, drug, and crushed 
filament was performed using a Shimadzu 6000 X-ray diffractometer (Shimadzu 
Corporation, Kyoto, Japan) with Cu-Ka monochromator emitting x-rays. Radiations of 
60 kV and 55 mA was used for analysis between 10 and 60° at a ramp of 2°/min. 
Samples were placed in glass cavities and were compressed using a glass slide for even 
distribution of the surface. 
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4.3.5. Egglet shaped 3D printing of MET extrudates 
 
 
MakerBot® Replicator 2 desktop single nozzle 3D printer (MakerBot Inc., 
USA) with 0.4-mm nozzle was used for fabricating egglets. Initial template for oval 
tablets, i.e., egg-shaped tablets (egglets) were designed using TinkerCad online 3D 
designing software and saved in .stl file format. Design was imported to 3D printer 
software MakerWare™ (v. 2.2.2). The oval design was selected based on structural 
integrity and its geometry for crush resistance. 
 
 
It was hypothesized that, when force applied to an egglet versus a conventional 
tablet (flat and round), the distribution may not be uniform in oval shape, due to the 
bulge in the Z-axis across. Egglets were printed using MET-loaded filaments as feed 
to printer. Dimensions of small egglet (SE) and big egglet (BE) are given in Table 6. 
Printing was done in two infill percentages (density) 45% and 90% in hexagonal 
printing infill pattern. 
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The following printer settings were utilized for printing: standard resolution 
without activating the raft, supporting and bridging option, nozzle temperature was set 
at 200°C (lower temperatures resulted irregular deposition), build plate was maintained 
at room temperature, printing speed of extruder was set at 45 mm/s while extruding and 
150 mm/s when traveling. Printing was performed with a set top and bottom layer 
thickness of 1.6 mm and 1.6 mm respectively (to mimic the hard upper and lower shells 
of egg), by using two shells and 0.4 mm layer height. Precut Kapton tape was applied 
to the build platform for proper adherence of model to the surface. The individual 
weights of all egglets printed were mentioned in Table 7. 
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Table 6. Dimensions of egglets 
 
 
 
Dimension BE SE 
X 8 mm 6 mm 
Y 5.5 mm 4.4 mm 
Z 5 mm 3.3 mm 
BE Bigger egglet SE Smaller egglet 
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Table 7. Individual weights of egglets printed 
 
 
 
 
Run A: Drug load 
(%) 
B: 
Infill 
density 
(%) 
     C: X 
 
(mm) 
D: 
Y(mm) 
E: Z 
(mm) 
Weight(mg) Drug 
(mg) 
1 10 45 6 4 3.3 100 10 
2 5 90 8 5.5 5 250 12.5 
3 10 45 8 5.5 5 200 20 
4 15 90 8 5.5 5 250 37.5 
5 5 45 6 4 3.3 100 5 
6 10 90 8 5.5 5 250 25 
7 15 90 6 4 3.3 150 22.5 
8 15 45 8 5.5 5 200 30 
9 5 90 6 4 3.3 150 7.5 
10 10 90 6 4 3.3 150 15 
11 5 45 8 5.5 5 200 10 
12 15 45 6 4 3.3 100 15 
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4.3.6. Hardness/Crush resistance and friability testing 
 
 
Pharmaceutical hardness tester (Pharma Alliance Group, CA, USA) was used 
for characterizing the egglets’ hardness. The hardness tester was able to exert a 
maximum load of 50 kg (~ 500 N). All the measurements were done in triplicate. 
Friability test was performed using a HT-2 Friabilator USP (Sotax, Switzerland). 
Egglets (n = 10) were preweighed and placed inside the friabilator and rotated at a 
speed 25 RPM for 4 min. The egglets were reweighed and the percentage weight loss 
was calculated. 
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4.3.7. Physical manipulation and fine particle reduction 
 
 
Physical manipulation was carried out by using mechanical and power-driven 
electrical means. Common household equipment such as a knife, hammer, spoons, and 
graters were used to check the physical mechanical manipulation. Additionally, 
household electrical appliances with high shear, i.e., a coffee grinder (Brewberry, 
Bangkok) and laboratory equipment’s like a mortar and pestle, high shear analytical mill 
were also employed. The egglets were subjected to different manipulation conditions 
with varied levels of stress conditions for each equipment. Egglets were subjected to 
high shear grinding for 5 min using a coffee grinder and analytical mill. The resultant 
material was subjected to particle size distribution by sieve analysis. 
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4.3.8. In vitro drug dissolution 
 
In vitro drug release was performed using USP II dissolution apparatus 
(Symphony 7100, Distek, New Brunswick, NJ) in 900 mL of 0.1 N hydrochloric acid 
(HCl). The dissolution medium was maintained at 37 ± 0.3°C and were stirred at 100 
RPM paddle speed. Samples (3 mL) were withdrawn at specified time intervals of 5, 
10, 15, 30, 45, and 60 min and equal volume of fresh medium was then replaced into 
the dissolution vessels at each time point. Drug content in collected samples was 
analyzed using a UV spectrophotometer at 220 nm. All dissolutions studies were 
carried out in triplicates (n = 3). 
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4.3.9. Solvent Extraction 
 
USFDA recommends different levels of solvent to evaluate the drug extraction 
from ADF to minimize injection abuse. Drug extraction from egglets was tested using 
the solvents mentioned in Table 8. Initial extraction studies were carried out using level 
1 solvent, i.e., deionized water. Further, level 2 and level 3 solvents were employed for 
extraction studies. Each egglet was added to a glass vial with 5 mL of solvent and 
vortexed for 30 s. After 5 min, 20 μL of aliquots was withdrawn and diluted to 5 mL 
with distilled water. MET content in aliquot was analyzed using UV spectrophotometer 
at 220 nm. All the measurements were done in triplicates (n = 3). 
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Table 8. Various levels of solvents used for solvent extraction 
 
 
 
Level 1 Level 2 Level 3 
Deionized 
 
water 
40% v/v ethanol 100% ethanol, acetone 
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4.3.10. Quality by Design 
 
Response surface design was used to optimize D85 (i.e., time for 85% of 
cumulative drug release) and % Sext (i.e., percentage of drug extracted using water in 5 
min). Five definite factors which were utilized in development of formulation, i.e., drug 
loading (5%, 10%, and 15% w/w), infill density (45% and 90%), and dimensions (X, 
Y, and Z) were identified as critical quality attributes (CQA) (independent variables). 
 
 
D85 and % Sext were selected as responses (dependent variables). Response 
surface design was used to get maximum information with minimum experiments. D85 
<30 min and % Sext < 20% were set as quality target product profile (QTPP). 
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Design Expert® (11.0.3.0) was used to design the experiments. Twelve 
experiments with different levels of factors were performed. Identification and 
quantification of correlation between CQAs and dependent variables were carried out 
and polynomial equation explaining the main effect and interaction effect were derived. 
The relationship between independent variables (CQAs) on responses (D85 and % 
Sext) was demonstrated by response surface plot with regions of maxima and minima 
indicated by red and blue, respectively. Design layout with factors and responses is 
given in Table 9. All the experiments were executed in randomized manner to minimize 
the bias. Analysis of variance (ANOVA) was performed to evaluate the effect of each 
independent variable on time needed for D85 and % Sext at significance level, α = 0.05. 
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Table 9. Design Layout with factors and responses 
 
 
Run Factor 1 
A: Drug 
load (%) 
Factor 2 
B: Infill 
density 
(%) 
Factor 3 
C: X 
(mm) 
Factor 4 
D: Y 
(mm) 
Factor 5  
E: Z (mm) 
D85 
 
(min) 
%Sext in 
5 min 
1 10 45 6       4 3.3 40±2 15±5.3 
2 5 90 8   5.5 5 66±1 6±3.75 
3 10 45 8   5.5 5 67±3 4±2.83 
4 15 90 8    5.5 5 58±2 7±2.47 
5 5 45 6      4 3.3 41±1 11±2 
6 10 90 8   5.5 5 64±3 6±3.5 
7 15 90 6      4 3.3 40±1 12±4.4
1 
8 15 45 8   5.5 5 52±4 6±0.24 
9 5 90 6      4 3.3 39±2 9±3.5 
10 10 90 6      4 3.3 42±1 12±5 
11 5 45 8    5.5 5 60±2 4±3 
12 15 45 6       4 3.3 30±1 14±1 
51  
 
 
 
 
 
 
 
 
Fig. 9. Schematic representation for development and characterization of the abuse 
deterrent egglet. 
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4.4. Results and Discussion 
 
 
       4.4.1. Analytical Method (U.V) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Standard curve of Metformin HCl. 
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4.4.2. Hot melt extrusion of placebo polymers 
 
 
Printability of drug-loaded polymeric filaments through an FDM 3D printer is 
one of the major concerns. Not every polymer is suitable for printing. For conventional 
hot melt extrusion application, brittle filaments are desired because they need to be 
easily milled/crushed and compressed into a tablet. However, in the case of 3D printing, 
the filament should have necessary mechanical strength and flexibility for passing 
through the nozzle, i.e., the filament should possess optimum elasticity to avoid issues 
such as breaking and clogging the nozzle while 3D printing. Brittleness of filaments 
renders it difficult to print as they tend to break, and soft filaments pose a problem of 
getting squeezed by feeding gear inside extruder of printer. Therefore, our initial goal 
was to prepare HME filaments with appropriate mechanical strength to withstand force 
applied by the 3D printer. 
Ease of printability through the FDM 3D printer and hardness of printed egglets 
(desired hardness > 500 N) were considered for selecting an ideal polymer for the 
preparation of MET-loaded ADF. Affinisol™15LV was easy to extrude through HME 
but its filaments were fragile enough to break on the conveyer belt itself. Filaments of 
Kollidon®VA64 were a little sticky. On cooling, these filaments were found to be 
fragile, resulting in constant breaking inside printer extruder. Filaments prepared using 
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combination of Kollidon®VA64 and Affinisol™15LV (1:1) possessed higher 
mechanical strength but too brittle for a reproducible printing. HPC filaments were too 
soft which resulted in squeezing of filament between feeding gears. As a result, feeding 
gears were unable to push the filament at constant printing speed. Filaments prepared 
using Kollicoat® IR and PVA possessed enough mechanical strength and flexibility for 
printing. However, egglets printed using Kollicoat® IR/sorbitol (90:10 w/w) filament 
had very low hardness < 130 N whereas, egglets prepared using PVA/ sorbitol (90:10 
w/w) showed hardness of > 500 N irrespective of dimension, infill pattern, and 
percentage. Hence, based on printability and hardness results, PVA with 10% w/w 
sorbitol was found to be the most suitable polymer matrix for the preparation of 
immediate release egglets. The difference in the mechanical property of various 
polymeric filaments is due to their chemical composition. Affinisol™15LV and HPC 
are essentially a carbohydrate while PVA has a thermoplastic characteristic due to vinyl 
backbone. 
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4.4.3. Hot Melt Extrusion of Drug loaded filaments 
 
 
As mentioned above, PVA with 10% w/w sorbitol was chosen as optimized 
polymer blend for further studies. MET loaded PVA-sorbitol filaments with 5, 10, and 
15% w/w MET loading were successfully extruded with hot melt extrusion. Initially, 
extrusion was carried out at a barrel temperature of 140°C which resulted in hazy 
filaments due to incomplete melting of polymer blend. Also, at this temperature, 
significantly higher torque (> 70%) caused the extruder to stop automatically. At 
160°C, polymer blend began to melt but MET was not thoroughly mixed with PVA. 
Further increase in processing temperature to 170°C resulted in formation of 
homogenous glassy filaments. At this temperature, the material was melting properly 
thus resulting in extremely low processing torque (< 15%) which was in an acceptable 
range of operation. It can be hypothesized that, at this processing temperature sorbitol, 
a thermal lubricant has maximum plasticizing capacity. Our observation was in 
agreement with Lang et al., 2014 (Lang et al., 2014). Plasticizing effect of sorbitol 
during HME of PVA was reported previously by Tian et al., 2017 and Shemis et al., 
2013, where both the authors have indicated that -OH groups of sorbitol undergoes 
strong hydrogen bonding with PVA thereby reducing the interaction between PVA 
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molecules itself (Shmeis et al., 2013; Tian et al., 2017). The use sorbitol as a plasticizer 
was well reported in literature (Censi et al., 2018; Repka et al., 2008). 
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4.4.4. Solid state characterization 
 
 
              4.4.4.1. Differential scanning calorimetry 
 
 
DSC thermograms of pure components, physical mixture, and crushed 
filaments are shown in Fig. 11a. DSC scan of pure MET revealed a characteristic 
melting endothermic peak at 225°C which was in agreement previous literature 
reported by Hajare et al., 2012 (Hajare and Patil, 2012). DSC scan of the physical 
mixture showed a similar sharp melting endothermic peak at 225°C, indicating that the 
crystalline nature of active pharmaceutical ingredient (API) remained unchanged by 
the polymer during trituration process while preparing the physical mixture. DSC scan 
of PVA showed characteristic Tg and Tm at 54°C and 180°C, which were in accordance 
with the studies reported by W. De Jaeghere et al., 2015 and manufacturer’s technical 
information (Corporation, 2016a; De Jaeghere et al., 2015). DSC scan of sorbitol 
reported melting endotherm at Tm at 100°C which was in agreement with 
manufacturer’s technical information (Corporation, 2016b). Most importantly, an 
absence of sharp melting endotherm of MET in DSC scan of crushed filaments 
suggesting amorphization of API during HME. 
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4.4.4.2. X-ray powder diffraction 
 
 
XRPD pattern of pure components, physical mixture, and crushed filaments are 
shown in Fig. 11b. XRPD pattern of MET indicated distinct crystalline peaks at 2θ = 
17.5°, 24.4°, 31.3°, and 39.3° while PVA showed a broad peak between 2θ = 19°–25° 
due to its semi-crystalline nature(De Jaeghere et al., 2015). XRPD of the physical 
mixture also showed sharp crystalline peaks at 2θ = 17.6°, 24.5°, 31.3°, 39.4° denoting 
that the solid state of API and PVA was unaltered during trituration and blending. 
Characteristic crystalline peaks of API were completely absent in XRPD pattern of 
crushed extrudates (filaments). Crushed filaments did not show any sharp crystalline 
peak of MET, indicating amorphization of drug within polymer. Data of XRPD were 
very well in agreement with DSC results. 
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Fig. 11. Solid-state characterization 
 
 
a) Differential scanning calorimetry b) X-ray powder diffraction. Absence of MET 
endothermic peak in DSC and absence of crystalline peak in XRPD confirmed 
amorphization of drug during HME. 
a) b) 
60  
4.4.5. Egglet-Shaped 3D Printing of MET Extrudates 
 
 
The tablets were specifically printed in an egg shape with an aim to resist 
physical manipulations. Initially, FDM 3D printing of the extrudates to fabricate 
egglets was performed at different temperatures using a benchtop single nozzle FDM 
3D printer (MakerBot® Replicator 2, MakerBot, Brooklyn, NY). Egglets printed using 
the FDM 3D printer are shown in Fig. 12. The printing was done at various 
temperatures to optimize the minimum temperature required for printing. Printing 
performed at temperatures < 190°C resulted in the improper melting of feed material 
from nozzle. Hence, it resulted in significant surface imperfections due to nonuniform 
flow of the material from the nozzle. Melting and flow of the material were found to 
be uniform at 200°C. Thus, 200°C was optimized as the temperature for printing. 
Printing performed at this temperature yielded reproducible egglets, i.e., they had a 
minimum weigh variation (< 2 mg). Fabrication was done in bigger (BE) and smaller 
dimensions (SE) in three drug loadings as shown in Table 6 using two infill percentages 
(45% and 90%) in hexagonal infill pattern. Egglets printed in SE and BE dimensions 
had an average printing time of 1.5 min and 2 min, respectively. Irrespective of chosen 
infill density, the printing time remained constant based on dimension selected. 
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4.4.6. Hardness/Crush resistance and friability testing 
 
All the egglets fabricated using filaments of different drug loadings (5, 10, and 
15% w/v), infill percentages (45% and 90%), and sizes were found to withstand the 
maximum force applied by hardness tester. Interestingly, there was no deformation or 
change in the shape of the egglet even at the maximum force of hardness tester. Picture 
of egglets before and after hardness test is shown in Fig. 12. panels a and c, respectively. 
We assume that such a high mechanical strength of egglet is attributed to thermoplastic 
behavior of PVA with sorbitol. Additionally, internal egglet integrity was due to fused 
polymer bridges in layer by layer fashion, along with increased thickness on both sides 
resulted in very high mechanical strength. Hence, every hardness test (all the 
formulations from run1 to run 12) yielded in force required > 500 N (50 kg) as shown 
in Fig. 10b. Friability was less than 0.1% for all the egglets. Therefore, it can be 
concluded that the egglets were crush resistant as per the USFDA guidance and 
previously reported literature (Administration, 2017; Cailly-Dufestel et al., 2015; Food 
and Administration, 2015; Maincent and Zhang, 2016). It can be potentially helpful in 
defeating abusers’ interest towards snorting, injection, crushing, and chewing. 
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Fig. 12. USP hardness test a. Before test b. Egglet at maximum force c. After test. 
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4.4.7. Physical manipulation and fine particle reduction 
 
Manipulation efforts demonstrated that egglets cannot be cut, grated, or 
deformed using common household equipment. Household tools have low shear 
mechanical forces. It was essential to evaluate it because they are readily available to 
tamper the formulation. Manipulations performed using high shear electric grinders and 
lab analytical mills yielded a coarse powder/chunky material. Fig. 13. panels a and b 
show egglets before and after grinding in a coffee grinder and lab analytical mill, 
respectively. It was important to determine the particle size distribution (PSD) of 
dosage form manipulated by various mechanical means to understand the scope of nasal 
abuse. PSD of crushed egglets revealed that majority of the particle were far bigger 
than the snorting range. From sieve analysis, it was observed that > 80% w/w particles 
were greater than 1 mm and found to be coarse/chunky material. While < 10% w/w of 
particles were found to be above 840 μm, and > 99% of particles were greater than 
snortable range (> 500 μm) of particle size form the coffee grinder (Fig. 13c). Whereas, 
from analytical mill>90% of particles were greater than snortable range. From an 
abuser’s perspective, snorting is one of the preferred routes of abuse. It is one of the 
most convenient and major routes of abuse (Katz et al., 2011). Conventional tablet 
formulations are crushed to prepare a fine powder which could be inhaled 
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(snorted) to attain a state of euphoria (Khan and Gharibo, 2010). Intranasal inhalation 
can result in both bypassing the blood-brain barrier and hepatic first-pass metabolism 
(Maddineni et al., 2014). Whereas, nasal formulations possessing particle size of 10– 
20 μm is essential for application through nasal route but particle size > 100 μm might 
cause nasal irritation (Fransén et al., 2007). Based on the USFDA guidance in 2015 and 
previous literature, when the mass percent of fine particles (≤ 500 μm) is ≤10%then the 
product becomes unsuitable for nasal insufflation (Administration, 2017; Bartholomäus 
et al., 2013). Our study shows that even though the egglets could be crushed only by 
high shear milling for a longer time, it could not be crushed into fine particles viable 
for snorting. Thus, egglets can be an amenable method to deter abuse through 
tampering, injection, chewing, and snorting. 
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Fig. 13. Crush resistance and milling of optimized egglets in a. laboratory analytical 
mill and b. commercial coffee grinder and c. average particle size distribution of 
particles obtained after grinding in coffee grinder. 
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4.4.8. In vitro drug dissolution 
 
 
The dissolution data of egglets is shown in Fig. 14. It was observed that SE with 
15% w/w drug loading in smaller dimension with 45% infill density showed 85% of 
drug release in 30 min (Fig. 14c). On the other hand, egglets prepared using 5% w/w 
and 10% w/w drug loading were unable to achieve D85 < 30 min (Fig. 14 a and b). 
Primarily, drug loading played a vital role in dissolution rate of formulations followed 
by dimensions of egglets and infill density. Interestingly, egglets with 5% w/w drug 
loading and 90% infill density showed almost 27 min higher D85 for BE compared to 
SE. Similar trend was noted in egglets of 10% w/w and 15% w/w drug loading. 
Difference in D85 was less in egglets with 45% infill density. D85 was around 18 min 
shorter for SE compared to BE in egglets with 45% infill density. Thus, it was 
imperative to carry out a design of the experiment (DOE) to systemically investigate 
the effect of size, drug loading and infill density on D85. Detailed information about 
factors affecting D85 were given in quality by design (QbD) section. 
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Fig. 14. In vitro dissolution studies of egglets in 900 mL of 0.1N HCl (n=3) a. 5% w/w 
drug load b. 10% w/w drug load c. 15% w/w drug load. 
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4.4.9. Solvent extraction 
 
To evaluate the abuse deterrence properties for parenteral route of 
administration, it was essential to measure amount of drug extracted in small volume 
of solvent to check the viable of injection abuse. Smaller volumes of extraction solvent 
(5 mL) were used for the study based on the fact that more than 5 mL of volume is not 
suitable to fill and inject via syringe. USFDA guidance also recommends use of 5 mL 
extraction solvent. Another reason is to mimic the attempts to dissolve the formulation 
in a teaspoonful of solvent (5 mL) which was in accordance with previous literature 
(Cailly-Dufestel et al., 2015; Fransén et al., 2007; Kumar et al., 2013; Wening et al., 
2017). Extraction studies were performed in different household solvents as per the 
USFDA guidance (Table 8). 
Water was chosen as a first line of solvent for extraction studies as it is the most 
commonly available solvent for any abuser. Visual observation at 0 min (Fig. 15a) and 
after 5 min (Fig. 15b) in water revealed that egglets remained intact. After 5 min, 
egglets were vigorous vortexed for additional 10 min. But no change in egglets 
geometry was observed which confirmed that egglets would resist the dissolution in 
small volume of water. Amount of drug extracted in water depends up on infill density, 
dimensions, drug loading. Less than ≤ 15% of drug was extracted in 5 min from all the 
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batches of egglets (Fig. 15c). Hence, 3D-printed egglets can also deter the abuse 
through parenteral route of administration. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Solvent extraction at different time intervals. a Time = 0 min (t
0
). b Time = 5 
min (t
5
). c Percentage drug extraction in 5 min in 5 mL of water (% S
ext
). Solid black 
line indicates desired % drug extraction (< 20%). All solvent extraction studies were 
done in triplicate (n=3). 
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4.4.10. Quality by design 
 
 
Over the past decades, QbD has been promoted by the USFDA as a systematic 
approach to enhance pharmaceutical development through design efforts. The QbD has 
two main objectives: (a) designing a method in a path that pharmaceutical manufacture 
consistently meets critical quality attributes and (b) understanding and controlling the 
impact of formulation components and process parameters over critical quality 
attributes (Chobisa et al., 2018; Mishra and Rohera, 2017; Saurí et al., 2014). To get an 
insight into both the main and interaction effects of formulation and process factors, 
DOE have been employed. In our study, response surface design was chosen as our 
DOE to optimize the D85 and % Sext. 
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4.4.10.1. Statistical analyses of responses D85 
 
 
Responses obtained for D85 by changing various CQAs are shown in Table 9. 
ANOVA (Table 10) showed that model was significant (p < 0.0001). Values of 
coefficient of determination R2, adjusted R2, and predicted R2 were 0.9057, 0.8847, and 
0.8271, respectively. The predicted R2 of 0.8271 was in reasonable agreement with 
adjusted R2 of 0.8847. The model having difference of less than 0.2 between predicted 
R2 and adjusted R2 was good for prediction purpose. As shown in Table 10, it was evident 
that higher the infill degree, lesser the water penetration into the egglet, which resulted 
in longer D85. Increase in drug loading resulted in shorter D85. While, increase in X 
dimension resulted in longer D85. ANOVA (Table 10) suggested that amongst all 
CQAs, only X dimension was a major contributor while drug loading was not a 
significant factor for D85. Further based on response surface plot (Fig. 16a) and contour 
plot (Fig. 16b), it was clear that, infill density has no effect on D85 while it was 
substantially affected by drug loading, even though ANOVA states that X dimension p 
value is 0.0682 (Table 10). 
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The following polynomial equation has been generated to establish the relation 
between CQAs and D85 as: 
Actual Equation: D85= -22.68917-0.631250*Drug load+11.27333*X .................... (1) 
 
 
Fig. 16b. shows the contour plot for effect of independent variables on D85. Based on 
Eq. 1, X dimension has positive effect for D85 response, whereas, drug loading has 
negative effect on D85. 
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Table 10. Analysis of Variance (ANOVA) for Statistical Analyses of D85 
 
 
 
Source Sum of Squares df Mean 
 
Square 
F-value p-value  
Model 1604.75 2 802.38 43.21 < 0.0001 significant 
A-Drug load 79.70 1 79.70 4.29 0.0682  
C-X 1525.06 1 1525.06 82.13 < 0.0001 significant 
Residual 167.11 9 18.57    
Cor Total 1771.87 11     
 
 
 
D85 Time taken for 85% of cumulative drug release 
X mm dimension A (Factor 1) Drug load 
Cor, correlation 
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Fig. 16. a. Response surface plots of D85 and b. contour plot of D85. 
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 4.4.10.2. Statistical analyses of responses %Sext 
 
 
As shown in Table 9, various responses were obtained for % Sext by changing 
CQAs. ANOVA (Table 11) showed that model was significant (p < 0.0001). Values of 
coefficient of determination R2, adjusted R2, and predicted R2 were 0.9544, 0.9283, and 
0.8753, respectively. The predicted R2 of 0.8753 was in reasonable agreement with 
adjusted R2 of 0.9283. The model having difference of less than 0.2 between predicted 
R2 and adjusted R2 was good for prediction purpose. Irrespective of drug loading, 
higher amount of drug extraction was observed from SE compared to BE. Increase in 
% infill density from 45% to 90% resulted in reduced drug extraction from all the 
formulations. The following polynomial equation has been generated to establish the 
relation between CQAs and % Sext as. 
Actual Equation: %Sext in 5min= +51.91583+0.237750*Drug load-0.330741*% infill 
density-6.47000*X+0.046407*(infill density*X) ................. (2) 
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ANOVA (Table 11) analysis suggested that infill density has no significant 
effect (p value 0.6722) on % Sext. Moreover, from Eq. 2 and ANOVA, drug loading has 
a positive and significant effect on % Sext. X dimension has a negative but significant 
effect on response. Fig. 17b. shows the contour plot for effect of independent variables 
on % Sext. As depicted in the contour plot, increased drug load resulted in increase in 
the amount of drug extracted. Whereas, increase in X dimension caused reduction in 
the amount of drug extracted. It was evident from contour plot that % infill density has 
no effect on % Sext. Interaction graph of % Sext versus infill density showed very 
interesting data. %Sext was reduced with increase infill density in (X = 6 mm) small 
dimension egglet (SE) but opposite behavior was observed in egglet with bigger 
dimension (BE). Irrespective of drug loading, egglet with smaller dimension (SE) 
showed reduction in% Sext with increase in % infill density. 
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Table 11. Analysis of variance (ANOVA) for statistical analyses of % Sext 
 
 
Source Sum of Squares df Mean 
 
Square 
F-value p-value  
Model 158.27 4 39.57 36.59 < 0.0001 significant 
A-Drug load 11.31 1 11.31 10.46 0.0144 significant 
B-Infill density 0.2107 1 0.2107 0.1948 0.6722  
C-X 133.67 1 133.67 123.62 < 0.0001 significant 
BC 13.08 1 13.08 12.10 0.0103  
Residual 7.57 7 1.08    
Cor Total 165.83 11     
 
 
 
% Sext in 5 min Percentage of drug extracted using water in 5 minutes 
 
 
X mm dimension A (Factor 1) Drug load B (Factor 2) Infill density C 
 
 
(Factor 3) X mm dimension 
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Fig. 17. a. Response surface plots of % Sext and b. contour plot of % Sext. 
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4.4.10.3. Optimization 
 
 
After analyses of responses and development of proper regression models, 
optimization was done to select design space. Criteria were set for D85 and %Sext to 
achieve shorter D85 and minimum % Sext. To achieve these pre-set criteria with 95% 
confidence, the software suggested ranges of factors using desirability function. Further 
to confirm this, validation trials in triplicate were performed using SE of 5% w/w drug 
loading with 90% infill density. Results were found to be within 95% confidence 
interval of the predicted value (Table 12). Based on obtained design space, optimized 
setting of 15% w/w drug loading with 45% infill density in SE dimension was further 
selected for level 2 and level 3 extraction studies as per the USFDA guidance. 
Extraction studies employing level 2 and level 3 solvents were performed in triplicate. 
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Table 12. Results of confirmation trials 
 
 
Response Predicted 
Mean 
 Observed n 95% 
PI 
low 
95% PI 
high 
D85 41.7946 39.21 3 34.0882 49.5009 
% Sext in 5 
min 
9.57792 8.68 3 7.39015 11.7657 
D85 Time taken for 85% of cumulative drug release 
 
 
% Sext in 5 min Percentage of drug extracted using water in 5 minutes 
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4.4.11. Solvent Extraction in Level 2 and Level 3 Solvents 
 
 
Optimized egglet showed < 30% and < 10% of drug extraction in 40% ethanol 
(level 2) and 100% ethanol (level 3), respectively. Moreover, the amount of drug 
extracted in acetone (level 3) was below the range of detectable limit. Very limited 
extraction of drug was attributed to PVA-based matrix. As per manufacturer’s technical 
information, PVA (Parteck®MXP) has minimal or very limited solubility in ethanol and 
acetone (Corporation, 2016a). 
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            5. Development of multi-dose oral abuse deterrent formulation  
            of Loperamide using Hot melt extrusion 
 
       5.1. Introduction 
 
 
5.1.1. Drug (Loperamide Hydrochloride) 
 
Chemically loperamide is a derivative of phenylpiperidine, which is an opioid 
agonist. Initially classified in the US under a Schedule II, it was later shifted to a 
Schedule V in 1977; from 1982 it has not been identified as a controlled substance and 
is available OTC without a prescription. Pharmacologic effect is attained primarily by 
binding peripherally as a µ-receptor agonist on the mesenteric plexi of enteric wall. By 
administering in therapeutic doses (8mg/day) it reduces the gastrointestinal motility. 
Therapeutically, loperamide is used for treatment of diarrhea including traveler’s 
diarrhea and gastrointestinal inflammation. Loperamide Hydrochloride drug profile 
was outlined in Table 13. 
84  
Table 13. Drug Information (Loperamide Hydrochloride) 
 (Adapted from Ben- Hander et al., 2015; Kasim et al., 2004; Kortejärvi et al., 2014) 
 
 
Name Loperamide hydrochloride 
 
Chemical Name 
4-(p-chlorophenyl)-4-hydroxy-N, N-dimethyl- a, a- 
 
diphenyl-1-piperidinebutyramide monohydrochloride 
Molecular formula C29H34Cl2N2O2 
Molecular weight 513.5 g/mol 
Structure 
 
 
CAS No. 53179-11-6 
Description Phenyl piperidine derivative 
Melting point 223-226℃ 
Partition coefficient 4.7 
Solubility 0.00086 mg/mL in water 
BCS class Class IV 
Dosage Dose: 2mg – 8mg 
Indication and use Anti-Diarrheal drug 
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5.1.2. Abuse of novel psycho active substances (NPS) 
 
 
Recently, the abuse of prescription drugs has been rising at a higher rate, 
causing greater threat to public health in the United states (Nukala et al., 2019b). 
Simultaneously, the deaths associated with the opioid epidemic is increasing during 
recent years (Miller et al., 2017). Due to the limited availability of prescription opioids 
and emergence of abuse deterrent formulations by the USFDA, the modern-day abusers 
have been shifting towards NPS (Schifano et al., 2018). A range of prescription (e.g. 
Pregabalin, Gabapentin etc.) and OTC drugs (e.g. Loperamide, Dextromethorphan etc.) 
were categorized as NPS’s due to their scope of abuse from large doses, which yields 
intense psychoactive action and cannot be diagnosed in drug screenings (Schifano et 
al., 2018). 
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5.1.3. Abuse of Loperamide Hydrochloride 
 
 
A perfect example is an OTC anti-diarrheal drug, loperamide. This OTC 
medication is gaining popularity as a drug of abuse for attaining euphoria and for 
amelioration of opioid withdrawal symptoms (Lasoff et al., 2017; Miller et al., 2017). 
Due to its ease of availability and very low price, loperamide, is gaining interest among 
many opioid abusers (Katselou et al., 2017). Numerous reports indicate loperamide to 
be alternative for opioids. Based on National Poison Database System (NPDS) between 
2008 and 2016 there has been a significant increase in loperamide misuse with 179 
reported cases. In addition, more than 50% reports were noted after January 1, 2014 
(Miller et al., 2017). Between 2010 and 2015, the NPDS have reported a total of 1736 
reports of intentional abuse (Borron et al., 2017; Wu and Juurlink, 2017). 
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5.1.4. Multidose oral abuse of Loperamide Hydrochloride/ Poor Man’s 
Methadone 
Loperamide is sold as a hydrochloride salt under the trade name Imodium®/A- 
D or in generic form as an anti-diarrheal drug (Katselou et al., 2017). It is available in 
forms of a tablet, capsule, and liquid at a recommended dose not exceeding 8 mg/day 
(nonprescription) or 16 mg/day (prescription) (Miller et al., 2017). After ingestion of 2 
mg of loperamide HCl the plasma levels of drug remained under 2 ng/mL. Hence, it is 
regarded as safe for oral ingestion in therapeutic doses only. However, when ingested 
in elevated doses, it has been reported to alleviate the symptoms of opioid withdrawal 
by various drug use websites including drug forums online from 2005. Being a choice 
for drug of abuse due to its associated euphoric effects at larger quantities of 60 mg, it 
acts as a possible alternative to methadone, hence it is often regarded as “poor man’s 
methadone” (Daniulaityte et al., 2013; Katselou et al., 2017). Based on the USFDA 
report, loperamide abuse and misuse initiates, especially at doses of 60 mg (around 30 
tablets) (Inc., 2016; Jaffe et al., 1980).In a survey an abuser reported to ingest an 
average amount of 70 mg to several hundred mgs (1600 mg) a day (Katselou et al., 
2017; Wu and Juurlink, 2017). We have also referred to the experiences of loperamide 
abusers described on websites like bluelight, drugs forum, erowid (Katselou et al., 
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2017; Wu and Juurlink, 2017). Loperamide has a low potential for central nervous 
system (CNS) effects when administered in therapeutic doses (Katselou et al., 2017).In 
the case of ingesting doses higher than recommended, it has an ability to permeate into 
the CNS which increases the half-life. The average elimination half-life (t1/2) of 
loperamide was reported to be 10.8 hours, having a range of 7-15 hours. However, 
when overdosed the half-life increased to 41 hours (Wu and Juurlink, 2017).Normally 
it is unable to pass through the Blood brain barrier (BBB) and has poor bioavailability 
(0.3%), but in high doses it can induce effects on the CNS (Bruni et al., 2013; Katselou 
et al., 2017). Respiratory depression, cardiac dysrhythmia and vision impairment were 
found to be associated with supratherapeutic doses of loperamide (Lasoff et al., 2017). 
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5.1.5. USFDA plan of action to reduce loperamide Hydrochloride abuse 
 
Recently on (January 30th, 2018), the USFDA recommended a safety prevention 
for the manufacturers to prepare blister packs or single dose packaging to limit the 
number of doses in a package (USFDA, 2018a). The USFDA urges patients to follow 
package instructions while using loperamide. In addition, the USFDA informs health 
care professionals to consider loperamide as a possible cause of cardiac events 
(USFDA, 2018b). Naloxone is commonly used to treat loperamide overdose. But to 
overcome the overdose toxicity activated charcoal is preferred, only if the patient’s 
mental status is active (Katselou et al., 2017; Wu and Juurlink, 2017). 
Thus, in this work, we have demonstrated the proposed concept. Two gastric 
pH soluble polymers Eudragit® EPO and Kollicoat® Smartseal 100P were investigated 
as acid soluble matrix in the preset work. Initially, LPH loaded filaments were prepared 
using pH sensitive (gastric pH soluble) polymers by HME. Amount of free base needed 
to raise the pH >5 in various media was evaluated. Tablets comprising of crushed 
extrudates and specific amount of base were prepared and characterized. In vitro 
dissolution of single and multiple tablets of Imodium® and SJU tablets were carried out 
in biorelevant media. 
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              Fig. 18. Schematic diagram of proposed study (LPH). 
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       5.2. Materials 
 
 
Loperamide hydrochloride (LPH) was purchased from AK Scientific, Inc. 
(Union city, CA). Imodium® tablets were purchased from Rite Aid Pharmacy. 
Eudragit® EPO was generously gifted by EVONIK® (Parsippany, NJ). Kollicoat® 
Smartseal 100P and Kollidon® CL were kindly donated by BASF (Florham Park, NJ). 
L-arginine was purchased from Alfa Aesar (Tewksbury, MA). Avicel® PH 102 was 
obtained as a gift from FMC BioPolymer (Philadelphia, PA). Acetonitrile (HPLC 
grade) and salts (HPLC grade) for preparing buffer in mobile phase were purchased 
from Fisher Scientific Co. (Pittsburgh, PA). Biorelevant media ingredients lecithin, 
pepsin, sodium taurocholate, sodium chloride, hydrochloric acid was purchased from 
Fisher Scientific Co. (Pittsburgh, PA). All materials were used as received. 
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       5.3. Methods 
 
 
 5.3.1. Analytical Method (HPLC) 
 
 
The drug content analysis was done using Waters alliance system equipped with 
2998 PDA (Photo diode array) detector and Cortecs™C18 column (4.6mm×50mm, 
2.7µm). Chromatographic separation was achieved using a mobile phase consisting 
5mMol Phosphate buffer (pH 3.5) and acetonitrile (ACN) (50:50, v/v). The flow rate 
was maintained at 0.25 mL/min with an injection volume of 5µL. Empower 3 software 
was used to monitor and process output signal. The column was maintained at room 
temperature (25oC) and detected at a λ max of 219 nm. The retention time was found to 
be 4±0.5 minutes. For drug content analysis the following method was used; 100 mg 
samples (LPH loaded crushed filament) was accurately weighed and placed in 50 mL 
volumetric flask. This was followed by addition of 25 mL of ACN to volumetric flask 
and sonicated for 15 minutes. Later the volume was made up to 50 mL with 5 mMol 
phosphate buffer (pH 3.5) and continued sonication for an additional 30 minutes to 
obtain a clear homogenous solution. The resultant solution was subjected to filtration 
using 0.45µm syringe filters (nylon). The filtrates were loaded into HPLC vials for drug 
content analysis. All measurements were made in triplicate (n=3).
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5.3.2. pH solubility profile 
 
 
Saturation solubility of LPH was evaluated between pH 2 -10.5. Excess amount 
of LPH was added to each tube containing 3 mL of phosphate buffer pH 2, pH 4, pH 6, 
pH 7.5, pH 9, pH 10.5, respectively. After addition of LPH, the individual tubes were 
continuously stirred for 24 hours on a mechanical shaker maintained at 37oC. Following 
24 hours of equilibration, the tubes were centrifuged at 6000 rpm for 10 minutes to 
obtain visually clear supernatants. Clear aliquots were withdrawn from each tube and 
filtered using 0.45µm syringe filters (nylon). The concentration of LPH in filtrate was 
analyzed using HPLC. All measurements were done in triplicate (n=3). 
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5.3.3. Hot melt extrusion of Loperamide Hydrochloride loaded filaments 
 
 
Hot melt extrusion was carried out using 11mm parallel twin screw melt extruder 
(Process 11, Thermo Fisher Scientific, Waltham, MA) comprised of 8 electric heating 
zones with an L/D ratio of 40. For the preparation of LPH loaded filaments two different 
polymeric blends were prepared using Eudragit® EPO and Kollicoat® Smartseal 100P, 
respectively and extruded individually. LPH and each polymer were weighed 
accurately in a 1:49 weight ratio (2% w/w drug loading) and thoroughly mixed in a 
Turbula® mixer (Willy A. Bachofen, Switzerland) for 30 minutes to obtain 
homogenous blend. The resultant homogenous mixtures were fed to heated melt 
extruder at a feeding rate of 2 g/min and processed at 150oC (individual zone 
temperatures were summarized in Table 14), by maintaining a die temperature of  160 
℃ and extruded using a circular 2.0 mm die with 250 rpm screw speed. Three screw 
designs of extruder were evaluated for processing the drug polymer homogenous 
mixture. Ludovic® simulation software (Saint-Etienne, France) was used to 
demonstrate the three screw configurations as shown in Fig. 19. First screw design 
(SDA), second screw design (SDB) and third screw design (SDC) were designed to 
have three (KA1, KA2, KA3), two (KB1, KB2) and one kneading zones (KC1). Every 
screw design possessed conveying zones in addition to a kneading zone. The screw 
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design for HME along with processing temperatures was selected based on torque 
analysis and physical appearance of extrudates. The extruded filaments were placed 
and properly sealed in plastic bags and stored at room temperature before subjected to 
milling. 
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Fig. 19. Three screw designs (SDA, SDB, SDC) of Hot melt extrusion. Lower shear 
screw design (SDC) was found to be most suitable for extrusion. 
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Table 14. HME heating zones and associated temperatures respectively. 
 
 
Zone # Temperature ℃ 
Zone 1(feeding zone) 25 (room temperature) 
Zone 2 30 
Zone 3 70 
Zone 4 90 
Zone 5 120 
Zone 6 140 
Zone 7 150 
Zone 8 150 
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5.3.4. Thermogravimetric analysis 
 
 
Thermogravimetric analysis (TGA) was performed to evaluate the thermal 
stability using a thermogravimetric analyzer, TGA Q50 (TA Instruments, Newcastle, 
Delaware, USA). TGA studies were done according to literature (Palekar et al., 2019). 
Pure LPH, neat polymers Eudragit® EPO, Kollicoat® Smartseal 100P, individual 
physical mixtures and crushed filaments were used for TGA. Samples of about 5 mg 
were accurately weighed and placed on a tared platinum pan. Prior to analysis, samples 
were held for one minute at 30 ℃ under nitrogen purge. During analysis, the temperature 
ramp was operated at a rate of 5 ℃/min. The percentage weight loss from individual 
samples was determined by heating from 30 ℃ to 300 ℃ under a constant nitrogen purge 
of 20mL/min. The obtained data was analyzed using TA instruments universal analysis 
2000 software. 
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5.3.5. Solid state characterization 
 
 
Solid-state characterization of pure LPH, neat polymers Eudragit® EPO, 
Kollicoat® Smartseal 100P and their associated physical mixtures of drug and polymer 
along with crushed filaments was carried out using differential scanning calorimetry 
(DSC) and X-ray powder diffraction (XRPD). 
              5.3.5.1. Differential scanning calorimetry 
 
 
DSC thermograms of samples were generated using a Q200 modulated DSC 
instrument (TA Instruments, New Castle, Delaware, USA) as per the literature (Nukala 
et al., 2019b). About 5 mg of samples were accurately weighed and placed in a Tzero® 
aluminum pans which were hermetically sealed. The experiments were conducted 
under a continuous nitrogen purge at a flow rate of 50 mL/min. For initial 5 minutes, 
the samples were equilibrated at 25°C. Later, the samples were subjected to heating 
from 25°C to 250°C at a heating rate ramp of 5°C/min along with modulation of 
1°C/min. The collected data was analyzed using TA instruments universal analysis 
2000 software. The temperature scale of instrument was calibrated using Indium as 
standard. 
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5.3.5.2. X-ray powder diffraction 
 
 
Samples were characterized by X-ray powder diffraction (XRPD) using 
Shimadzu 6000 X-ray diffractometer (Shimadzu Corporation, Kyoto, Japan) based on 
literature (Nukala et al., 2019b). Before obtaining diffraction patterns, the sample 
specimens for the XRPD analysis were prepared by placing samples on a metal sample 
holder with cavity, followed by pressing the material to obtain smooth and uniform 
surfaces. Samples were analyzed through a CuKa, monochromatic radiation source 
emitting X-ray radiation with generated voltage of 40 kV and current of 30 mA 
respectively at room temperature. The diffraction patterns of samples were obtained by 
scanning over a continuous 2θ range of 10°– 40° at a rate of 2 °C/min using a 0.02° step 
size. 
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5.3.6. Selection of free Base 
 
 
Commonly used alkalizing agents (Magnesium hydroxide, Calcium carbonate, 
sodium bicarbonate, L-arginine) were evaluated to find out the minimum amount for 
raising the pH > 5 in 250 mL of FaSSGF. 250 mL of media was based on realistic 
volume of fasted state in humans after assuming administration of drug product with 
8oz (glass) of water. 
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    5.3.7. L-arginine titration 
 
 
Amount of base (L-arginine) required to increase the pH>5 in various 
solutions was determined by titrating L-arginine solution against various media. 
Initially stock solution of 100 mg/mL of L-arginine was prepared in water. The L-
arginine solution was titrated with 250 mL of biorelevant media - Fasted state 
simulate gastric fluid (FaSSGF). 250 mL of media was based on realistic volume of 
FaSSGF after assuming administration of drug product with 8oz (glass) of water 
(Fiolka and Dressman, 2018; Food and Administration, 2017; Mudie et al., 2014). 
Usually in some severe cases abusers consume commonly available fluids like 
grapefruit juice (interacts with metabolism of LPH), aerated drink and beer along with 
drug to get high. By considering these severe cases, the additional titrations were 
performed by incorporation of 12 oz aerated drink, 4 oz grapefruit juice, 12 oz beer 
to 250 mL of FaSSGF respectively. Change in pH was constantly monitored during 
titrations. Volume of L-arginine solution was noted to calculate amount of L-
arginine required to raise pH of FaSSGF above 5. FaSSGF was prepared with the 
protocol mentioned by (Otsuka et al., 2013). Composition of FaSSGF is summarized 
in Table 15. 
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Table 15. Composition of Fasted State Simulated gastric fluid 
                  (Adapted from Otsuka et al., 2013) 
 
 
 
Ingredients FaSSGF 
Lecithin (mM) 0.02 
Sodium taurocholate (mM) 0.08 
Pepsin (mg/mL) 0.1 
Sodium chloride (mM) 34.2 
Hydrochloric acid (mM) 25.1 
pH 1.6 
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5.3.8. Tabletting 
 
LPH loaded filaments were milled using laboratory analytical mill and passed 
through series of sieves # 40, #60, #80 and #120 using a sieve analyzer (CSC Scientific, 
Fairfax, VA) at a vibration of 2mm amplitude for 10 minutes. The powder passed 
through sieve #40 and retained on sieve #60 was further used for tablet preparation. 
The composition of tablet blend is mentioned in Table 16. The tablet blend was mixed 
thoroughly in a Turbula® mixer (Glen Mills, Clifton, NJ) for 30 minutes prior 
compression. Tablets were compressed at pressure of 3000 lbs using flat face punches 
of 8 mm diameter (Natoli Engineering, Saint Charles, MO) on a single punch Carvar 
press assembly (Carvar Inc.). The die-wall was cleaned and pre-lubricated with 
magnesium stearate before each compression. The tablet blend was hand filled into the 
die before compression. Tablets compressed using Eudragit® EPO based filaments and 
Kollicoat® Smartseal 100P based filaments were labeled as SJU1 and SJU2, 
respectively. 
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Table 16. Formulation composition of tablet (each weighs 275 mg) 
 
 
Ingredients 
 
(mg)/tablet 
SJU1/ 
 
SJU2 
Milled filaments 100 
Avicel® PH102 50 
L-arginine 100 
Kollidon® CL 25 
#SJU1 = Crushed filaments of LPH loaded Eudragit® EPO; 
 
 
SJU2 = Crushed filaments of LPH loaded Kollicoat® Smartseal 100P 
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5.3.9. Physical characterization of Loperamide Hydrochloride Tablets 
 
 
Tablets were evaluated for thickness, diameter, weight variation, hardness and 
friability. For testing the weight variation 20 different tablets were selected and weighed 
on an electronic balance (Sartorius, Gottingen, Germany). Friability test was performed 
using a HT-2 Friabilator USP (Sotax, Switzerland). Randomly selected tablets (n = 10) 
were preweighed and placed inside the friabilator and rotated at a speed 25 RPM for 4 
min as per USP. Later, the tablets were reweighed, and the percentage weight loss was 
calculated. Pharmaceutical hardness tester (Pharma Alliance group CA, USA) was used 
for testing the tablet hardness. The tensile strength of tablets was calculated using the 
tablet breaking force and measured dimensions as per the standard procedure given by 
Fell et al (1970) (Fell and Newton, 1970). All hardness and tensile strength 
measurements were done in triplicate (n=3). 
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5.3.10. In vitro drug release 
 
 
5.3.10.1. Single unit dissolution 
 
 
In vitro drug release was carried out in 250 mL of FaSSGF using USP II 
dissolution apparatus (Symphony 7100, Distek, New Brunswick, NJ). The dissolution 
medium was maintained at 37±0.5oC and stirred at 50 rpm paddle speed. Single unit 
dissolution study was carried out for Imodium®, SJU1 and SJU2 tablet individually. 
Samples (4 mL) were withdrawn at predetermined time intervals of 5, 10, 15, 20, 30 
and 45 minutes. At each time point, equal volume of fresh dissolution medium 
(maintained at 37oC) was replaced into the dissolution vessels. Withdrawn samples 
were filtered through 0.45µm syringe filters (nylon) and filtrates were analyzed for 
drug content using HPLC. 
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5.3.10.2.  Multi-unit dissolution 
 
 
To evaluate deterrence to multi dose abuse, dissolution study with multiple 
tablets was carried out. This study was conducted by adding multiple tablets in the 
dissolution vessel at a time. 15 tablets of Imodium®, SJU1 and SJU2 tablets added to 
each dissolution vessel. Samples were collected at predetermined time intervals as 
mentioned in single unit dissolution. Similar to single unit dissolution, fresh dissolution 
medium was added at every time point. The collected samples were filtered using 
0.45µm syringe filters (nylon). Drug release at various time intervals was analyzed 
through HPLC. All dissolution studies (single and multi-unit) were carried out in 
triplicate (n=3). 
The formulation (SJU1 or SJU2) which will be able to obtain immediate release 
in single unit dissolution and negligible release in multi-unit (#15) dissolution will be 
selected for further studies. Next, optimized formulation (SJU Tablet) will be used for 
multi-unit dissolution with 30 tablets (mimic the conditions of abuse). Further the 
optimized formulation with single unit will be evaluated for drug release in various 
biorelevant media like FeSSGF, FaSSIF, FeSSIF. Finally step dissolution will be 
carried out for optimized formulation by taking single unit only. 
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Schematic presentation of proposed technology and experimental “proof of 
concept” is given in Fig. 20. 
 
 
 
 
 
Fig. 20. Schematic diagram for the development of multi-dose oral abuse deterrent 
formulation of loperamide using Hot melt extrusion. 
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       5.4. Results and Discussion 
 
 
5.4.1. Analytical Method (HPLC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21. Standard curve of Loperamide HCl. 
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Fig. 22. HPLC chromatogram of Loperamide HCl.
   Loperamide Hydrochloride  
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5.4.2. pH solubility study 
 
 
LPH showed pH dependent solubility which is attributed to basic nature of 
LPH. As shown in Fig. 23, pure LPH has a solubility of 1.02 mg/mL, 0.37 mg/mL and 
0.1 mg/mL at pH 2,4 and 6, respectively. Further increase in pH resulted in marked 
decrease in solubility to 0.02 mg/mL at pH 7.5. Thus, nearly 20-fold reduction in 
solubility was observed at neutral to slightly alkaline pH. No detectable solubility was 
observed at pH 10.5. Our observation was in accordance with Bruni et al (2013) (Bruni 
et al., 2013). 
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Fig. 23. Solubility of Loperamide Hydrochloride at various pH (n=3). Loperamide 
hydrochloride exhibited decreased solubility with increase in pH. 
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5.4.3. Hot melt extrusion of Loperamide Hydrochloride loaded filaments 
 
 
Three screw designs were evaluated for extrusion. Extrusion was carried out at 
150oC that is above the glass transition temperature (Tg) (52
oC) and below the 
degradation temperature (Td) (250
oC) for Eudragit® EPO. The processing temperatures 
for extrusion of Eudragit® EPO was in well accordance with literature (Parikh et al., 
2016). The torque generated during extrusion was monitored. As reported in Fig. 19, 
Extrusion with screw design - SDA (3 kneading zones (high shear)) resulted in sudden 
increase in torque (>90%) which led to automatic shutdown of extruder. Thus, 
impeding the flow of drug polymer mixture through the extruder. Similarly, second 
screw design (SDB) with two kneading zones (medium shear) resulted in high torque 
(>80%) causing extruder to cease. With screw design SDA and SDB the material was 
not melted properly resulting in solidification of components and blocking the 
path/channel. Interestingly, third screw design (SDC) with only one kneading zone 
(low shear) generated a torque of <60% (30%±5%) thus allowing the molten material 
to pass/flow throughout the length of extruder. Thus, SDC was used for further study. 
The design of the screw configuration/geometry of screws play a key role in 
processing the material through extruder (Crowley et al., 2007). Mainly, the alignment 
of screw elements permits the continuous flow of material through the extruder body. 
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Broadly two types of screw elements conveying, and kneading/mixing elements were 
used in extrusion process. Movement of material inside extruder possible through 
rotation of screws imparting shear and thermal energy on the material along with 
assisted heating zones. Conveying elements are responsible for conveying whereas, 
kneading elements are for mixing. The primary role of kneading elements is dispersive 
mixing, where the material gets captured locally in a pressurized region and gets 
squeezed. Kneading elements arranged in a series with different offset angles (forward) 
generates varied levels of shear depending on construction. Reducing the number of 
kneading elements decreases the intensity of mixing the material. By operating with 
initial design (SDA) the material (low Tg 52℃) might turned to a rubbery state before 
reaching the first kneading zone (KA1) (in between zone 3 and 4). This can be attributed 
to the increase in temperature from 30oC (zone 2) to 70oC (zone 3). KA1 composed of 
14 kneading elements aligned with progressive offset angles (0o-90o-0o-90o-0o-90o-0o- 
90-0o-60o-120o) forward. This kind of increase in number of kneading blocks with 
higher degree of offset angle provides more shear. Thus, KA1 imparts additional shear 
causing processed material to get trapped and squeezed between screws. Due to the 
gradual increase in temperature and alignment of kneading blocks, the rubbery material 
got stuck in between screws of KA1, thus restricting the further movement of screws. 
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This phenomenon resulted in blockage of the channel and triggering of torque. Hence, 
in a summary, the material was not mixed properly (material was not completely 
molten) due to its rubbery state and high shear of design causing increase in torque. In 
SDB the initial kneading zone (KB1) was present in zone 4 (90
oC) with 9 kneading 
elements (0o-60o-120o-0o-60o-120o-0o-60o-120o) having offset angles forward. 
However, even when attempted with SDB the conveyed material became rubbery in 
between zone 2 (30oC) and zone 3 (70oC) before entering KB1 in zone 4. Due to higher 
temperature of 90oC in zone 4, the material turned slightly molten when compared to 
nature of material in between zone 3 and 4 of SDA. Yet, the induced degree of molten 
nature was not considered enough for getting conveyed further from KB1 due to high 
imparted shear on material. So, it caused blockage of channel by getting trapped in 
between the screws of KB1, because of incomplete solidification. Whereas, by 
employing SDC majority of the fed material turned to melted state prior reaching (KC1) 
with 9 kneading elements (0o-60o-120o-0o-60o-120o-0o-60o-120o) with offset angles 
forward in zone 5 (120oC). The configuration of kneading elements in SDC was 
designed to have a low shear. Hence, progressive increase in temperature (30 oC-70oC- 
90oC-120oC) led to sufficient melting of mixture and proper mixing within kneading 
elements (KC1), thus facilitating the passage of mixed material through channel to end 
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of extruder. SDC was chosen as an optimized design for processing as it was able to 
produce clear extrudates. In some instances, the changes in configuration of screw 
elements help in melting, processing of materials properly and improving the flow 
through the extruder (Crowley et al., 2007). Consequently, SDC was selected further 
for extruding LPH loaded filaments using Eudragit® EPO and Kollicoat® Smartseal 
100P individually. Novel polymer Kollicoat® Smartseal 100P has a Tg of 50
oC (similar 
to Eudragit® EPO) hence the choice of using SDC has been warranted. Fig. 24. Plot 
indicated the % torque at different temperature for three screw designs. 
HPLC analysis of crushed extrudates of Eudragit® EPO and Kollicoat® 
Smartseal 100P revealed that drug content in both extrudates was found to be 
>98%±1.5. It means that drug is uniformly dispersed in the filaments and did not 
degrade. 
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Fig. 24. %Torque analysis at different temperatures for the three screw designs SDA, 
SDB, SDC. It was observed that SDC was optimum for extrusion based on % Torque 
analysis. 
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    5.4.4. Thermogravimetric analysis 
 
 
TGA was performed to evaluate the thermal stability of LPH and polymers to 
access their stability during hot melt extrusion. Fig. 25, illustrates the 
thermogravimetric analysis for LPH, polymers, physical mixtures and crushed 
filaments. LPH showed a negligible mass loss at temperatures <250℃ followed with 
a rapid mass loss at temperatures >250℃. There was no significant decrease in the 
% weight with an increment in temperature. It can be observed that over the course 
of the analysis, Eudragit® EPO and Kollicoat® Smartseal 100P exhibited a high 
thermal stability up to 200oC. Our results were in good accordance with literature 
reports (Liu et al., 2013; Porfiryeva et al., 2019). Similarly, crushed filaments from 
both polymers showed thermal stability up to 200oC. Altogether, TGA studies 
determined that the temperature for hot melt extrusion of 150℃ was suitable for the 
processing. 
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Fig. 25. Thermogravimetric analysis. LPH demonstrated thermal stability up to 250℃. 
Crushed filaments and neat polymers exhibited thermal stability up to 200℃. 
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    5.4.5. Solid state characterization 
 
 
DSC thermograms of LPH showed a sharp peak at 225oC corresponding to 
crystalline nature of drug (Fig. 26A). Our observation was in accordance with Bruni 
et al (2013) (Bruni et al., 2013). Glass transition temperatures (Tg) of Eudragit
® EPO 
and Kollicoat® Smartseal 100P were 52oC and 50oC, respectively. In either of the 
physical mixtures the characteristic melting endotherm for LPH was not visible. This 
is due to low LPH content (2%w/w) and it was insufficient to generate an endotherm. 
Crystalline peak of LPH was absent in crushed filaments. However, based on DSC 
results solid state of LPH in filament is difficult to predict because of absence of 
LPH endotherm in physical mixture itself. XRPD diffraction patterns were reported 
in Fig. 26B. X-ray diffractogram of pure LPH revealed 2-theta characteristic 
predominant crystalline peak at 16.52o along with some crystalline peaks of lower 
intensity at 13.14o and 18.7o. Our results were in accordance with Woertz et al 2015 
(Woertz and Kleinebudde, 2015). Furthermore, XRPD patterns of physical mixtures 
revealed a crystalline peak of very low intensity at 16.5o (indicating LPH) with a 
broad halo in majority of diffractograms. However, the lower intensity of peak was 
because of low amount of LPH in both mixtures. Interestingly, crushed filaments of 
both polymers did not show any LPH peak which confirmed that LPH is in 
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molecularly dispersed state. In case of Eudragit® EPO and Kollicoat® Smartseal 
100P the XRPD patterns exhibited a typical amorphous halo region for both 
polymers (Li et al., 2016). Moreover, filaments were very clear and transparent after 
extrusion which also confirmed that LPH is homogenously and molecularly 
dispersed within filament. Our observation was in accordance with previous reports 
(Genina et al., 2013). Hot melt extrusion is widely reported in literature to generate 
molecular dispersion of drug within polymer (Sarode et al., 2013). Amorphization 
or molecular dispersion of drug within filament is very important for long term 
stability of hot melt extrudates (Patil et al., 2016). 
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 Fig. 26. Solid state characterization A) Differential scanning calorimetry B) X-ray 
powder diffraction. Absence of characteristic melting endotherm (26A) and 
disappearance of sharp crystalline peaks (26B) in both the crushed filaments indicated 
LPH was molecularly dispersed in polymer after extrusion. 
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5.4.6. Selection of free base 
 
 
The amount required in raising the pH >5 for various alkalizing agents has been 
summarized in Table 17. Based on the shortest time required to raise the pH>5 L- 
arginine was selected for further studies. Because rest of the alkalizing agents required 
more >3 minutes in increasing the pH. Raising the pH rapidly (in < 1 minute) is of very 
pivotal to render the polymeric matrix insoluble and to retard the drug release. 
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Table 17. Time required for various alkalizing agents to raise the pH>5 
 
 
 
Alkalizing agent Amount (mg) Time (Sec.) 
Magnesium Hydroxide 200 >1200 
Calcium Carbonate 400 >1800 
Sodium Bicarbonate 1000 210 ± 30 
L-arginine 1200 8 ± 2 
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5.4.7. L-arginine titration 
 
 
Amount of L-arginine required to raise the pH >5 in various media is shown in 
Fig. 27. About 1.2 ±0.2 gm of L-arginine was required to raise the pH FaSSGF from 
1.6 to 5. We further estimated the amount of L-arginine required to raise the pH of 
FaSSGF mixed with fluid commonly consumed by abusers. After addition of aerated 
drink to FaSSGF the initial pH of mixture was 1.9 and it required 1.6±0.1g of L- 
arginine. Similarly, in case of beer the pH of mixture was 2.7 and it required 1.5±0.2 g 
of L-arginine. Co-administering grapefruit juice has been reported to enhance the LPH 
associated euphoria. Some abuser’s ingest grapefruit juice with LPH due to CYP3A4 
inhibitory effect of grapefruit juice (Alexander et al., 2014; MacDonald et al., 2015). It 
results in enhanced oral bioavailability of LPH. 
Therefore, titration was also carried out by adding 4 oz of commonly available 
grapefruit juice in to FaSSGF (initial pH 2.7). It required 2.7±0.3 g of L-arginine to 
raise the pH>5. We selected L-arginine as a base to raise the pH because it’s a non- 
essential amino acid that is consumed by humans in a regular diet (Wu et al., 2013). 
Daily acceptable dietary intake of L-arginine is about 20 g/day (Shao and Hathcock, 
2008). It is also a major ingredient of many OTC multivitamin supplements. In any 
aforementioned conditions of abuse, the amount of L-arginine needed to raise the pH 
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remained within the limit of average daily (20 g/day) intake. Based on results of this 
study, we decided to use the amount of L-arginine in each tablet. 
As mentioned previously, concept is to completely resist the release of drug 
from a polymeric matrix in case of multi-dose oral abuse. We decided to add, 100 mg 
in each tablet. So, when a diarrhea patient consumes 1-2 tablets, it will not change the 
pH of stomach. So, we can achieve complete solubilization of Eudragit® EPO and 
Kollicoat® Smartseal 100P and thereby complete LPH release. On the other hand, on 
consumption of 15 or more tablets at the same time, amount of L-arginine in the 
stomach will be increased to 1.5 g or higher. It will raise the pH of stomach to >8.5 as 
per our study. At this pH both the polymers are insoluble and as a result LPH will not 
be released from polymeric matrix. 
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Fig. 27. Titration of L-arginine in 250mL of biorelevant media (FaSSGF) and 250 mL 
of FaSSGF with Aerated drink (12oz.), Grapefruit juice (4oz.), Beer (12 oz.), 
respectively (n=3). FaSSGF: Fasted state simulated gastric fluid. Amount of L- 
arginine required to raise pH>5 various types of media were found to be well within 
the limit of daily recommended intake (20 g/day). 
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5.4.8. Tabletting and physical characterization of tablets 
 
 
The target loading of LPH in each tablet was 2 mg (equivalent to strength of 
marketed Imodium® tablets with inactive ingredients like Lactose, cornstarch, talc, and 
magnesium stearate). Ten randomly selected tablets each from SJU1 and SJU2 weighed 
on an average of 275 mg±2mg, thus ensuring uniformity in weight. Friability was found 
to be lower than 1% in both cases. Thus, confirming the mechanical stability of tablets. 
Hardness of tablet was 145±6.41N and 86±5 N for SJU1 and SJU2, respectively. While 
tensile strength of tablets was 2.43 ±0.11 MPa and 1.43±0.18 MPa for SJU1 and SJU2 
tablet when compressed at a pressure of 3000 lbs. Overall, SJU1 and SJU2 tablets meet 
the specifications described in manufacturing classification system (Leane et al., 2015). 
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             5.4.9.  In vitro dissolution 
 
 
             5.4.9.1. Single unit dissolution 
 
 
The dissolution data is presented in Fig. 28. Volume of 250 mL was used based 
on a) matching realistic volume to simulate the total fluid present in stomach for 
dissolving dosage forms during gastric residence state. Along with the fluid after 
administration in the fasted state making it around 250 mL (Vertzoni et al., 2005). b) 
Assuming administration of dosage form in healthy humans by co administration with 
8 fluid ounces of water (Fiolka and Dressman, 2018; Food and Administration, 2017). 
It was observed that both the tablets Imodium® and SJU1 exhibited >85% of drug 
release in 15 minutes. Thus, SJU1 met the criteria for immediate release tablet. 
Dissolution profile of SJU1 and Imodium® was found to be same. However, SJU2 
showed only 25% of drug release in 15 mins. SJU2 demonstrated poor drug release of 
<50% in 45 minutes as shown in Fig. 28A. Slower dissolution characteristics of 
Kollicoat® Smartseal 100P compared to Eudragit® EPO could be responsible for slower 
and sustained release of LPH from SJU2. 
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            5.4.9.2.  Multi-unit dissolution 
 
 
For evaluating the multidose oral abuse, the dissolution test has been performed 
by placing multiple tablets at once in dissolution vessel. Number of tablets was based on 
L-arginine titration plot in various media (Fig. 27). Dissolution profile of 15 tablets of 
Imodium®, SJU1 and SJU2 in 250 mL of FaSSGF is given in Fig. 28C. Commercial 
Imodium® tablets exhibited 90% of drug release in 30 minutes (Fig. 28C). Most 
interestingly, SJU1 and SJU2 were able to resist the drug release (Fig. 28C). Both groups 
showed <5 % LPH release which confirmed that multi-unit abuse of LPH can be 
prevented by SJU1 and SJU2. Pictures of dissolution jar of SJU1 single unit and multiple 
unit after 45 minutes of dissolution study are shown in Fig. 26B and Fig. 26D 
respectively. Dissolution jar of single unit SJU1 showed absence of any extrudate 
particles, indicating complete solubilization of LPH loaded Eudragit® EPO extrudates. 
Off-white particles in the jar were from microcrystalline cellulose. On the other side, 
dissolution jar of multi-unit SJU1 dissolution study contained many extrudates (pale 
yellow in color) that are not solubilized as shown in Fig. 28D. Further, we also plotted 
the amount of LPH release vs time from multi-unit dissolution study. From Fig. 29, it 
can be inferred that about 27 mg of drug was released from Imodium® within 30 minutes. 
Theoretically, 15 tablets of Imodium® should have 30 mg LPH. Thus, a person 
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consumes multiple tablet of Imodium®, proportionally high amount of LPH will be 
available for absorption. It’s worthy to note that, less than 1 mg of drug was released 
from SJU1 and SJU2 tablets throughout the dissolution. This observed difference of 
phenomenon might be due to increased pH in multi dose dissolution (more L-arginine) 
thus rendering the filaments insoluble and reducing drug release. Hence, this study 
demonstrates the ability of SJU1 and SJU2 formulations to withstand the drug release 
in comparison with Imodium® in multi-unit dissolution (mimicking multidose oral 
abuse). 
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Fig. 28. In vitro dissolution studies of Imodium® and SJU1 and SJU2 tablets in 250 mL 
of FaSSGF (n=3). FaSSGF: Fasted state simulated gastric fluid. A) Single unit 
dissolution B) Dissolution jar of single unit dissolution (SJU1) C) Multi-unit 
dissolution (#15 tablets) D) Dissolution jar of multi-unit (#15 tablets) dissolution 
(SJU1). 
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Fig. 29. Amount of drug released in multi-unit (#15 tablets) dissolution. Imodium® 
exhibited almost complete release of drug (~27 mg), while SJU1 and SJU2 were able 
to release <1mg throughout the dissolution. 
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Based on the above data, SJU 1 was able to provide immediate release and 
negligible release in single and multi-unit (#15 tablets) dissolution respectively. Hence 
for further studies SJU 1 was employed. From here with SJU 1 will be referred as SJU 
tablet. 
 
A comparative multi-unit dissolution (n=3) was carried out by taking 30 tablets 
of SJU tablet and Non-SJU tablet (without L-arginine). The dissolution study was 
carried out in 250 mL of FaSSGF. The pH was monitored continuously for initial 10 
minutes. It was observed that >90% of drug was released from Non- SJU tablet, 
exhibiting no resistance towards drug release. Whereas <5% drug release was noted for 
SJU tablet, there by indicating ability in resisting the drug release as shown in Fig. 30. 
This data was in well accordance with the pH vs time plot (Fig. 31), where the pH rose 
to 8 in dissolution jar of SJU tablet. On the contrary, the pH remained at 2 in the 
dissolution jar of Non-SJU tablet. 30 tablets of each SJU and Non-SJU tablets before, 
during and after dissolution were shown in Fig. 32. It was very evident that due to 
increased pH the LPH loaded filaments from SJU tablets were insoluble during 
dissolution and settled at the bottom of vessel at end (Fig. 32 A). On the other side in 
case of Non-SJU tablets the pH remained 2 in dissolution vessel, hence the LPH loaded 
filaments were solubilized in the vessel (Fig. 32 B). 
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Fig. 30. Multi-unit (#30 tablets) In vitro dissolution of SJU tablet and Non SJU tablet 
in 250 mL of FaSSGF (n=3). 
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Fig. 31. pH vs time plot. 
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Fig. 32. Multi-unit dissolution (#30 tablets) of A) SJU tablets (before, during and at 
end of dissolution) and B) Non-SJU tablets (before, during and after dissolution). 
A) B) 
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Dissolution in Fed state simulated gastric fluid (FeSSGF) was carried out using 
single unit SJU tablet (n=3) based on Koziolek et al., 2013 and Bou-chacra et al., 2017 
(Bou-Chacra et al., 2017; Koziolek et al., 2013). The total study was carried out in three 
separate conditions i. early stage pH 6.4 ii. Middle stage pH 5 iii. Late stage pH 3 as 
shown in Fig. 33. The composition of FeSSGF was outlined in Table 18. No drug 
release was observed in early and middle stages as the pH was ≥ 5 (Fig.33 A and B), 
where the Eudragit® EPO was not soluble. But in case of late stage (pH 3) >90% of drug 
release was observed (Fig. 33 C) and no traces of filaments were available at the bottom 
of vessel at end (Fig. 33 D). Our result was accordance with the properties of polymer 
(insoluble at and above pH 5) mentioned in handbook of pharmaceutical excipients 
(Raymond et al., 2012). 
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Table 18: Composition of Fed state simulated gastric fluid 
 (Adapted from Bou-Chacra et al., 2017; Koziolek et al., 2013) 
 
 
 
 
Ingredient 
 
Early stage 
 
Middle stage 
 
Late stage 
 
Sodium chloride (µM) 
 
148 
 
237.02 
 
122.6 
 
Acetic acid (µM) 
 
- 
 
17.12 
 
- 
 
Sodium acetate (µM) 
 
- 
 
29.75 
 
- 
 
Orthophosphoric acid (µM) 
 
- 
 
- 
 
5.5 
 
Sodium dihydrogen 
 
Phosphate (µM) 
 
- 
 
- 
 
32 
 
Milk/Buffer 
 
1:0 
 
1:1 
 
1:3 
 
Hydrochloric acid/Sodium 
 
Hydroxide q.s to pH 
 
6.4 
 
5.0 
 
3.0 
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Fig. 33. In vitro dissolution of Single unit SJU tablet (n=3) in 500 
mL of FeSSGF A) Early stage pH 6.4 B) Middle stage pH 5 C) Late 
Stage pH 3 D) Dissolution jar of late stage FeSSGF pH 3. 
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Next, dissolution was carried out for single unit SJU tablet in Fasted state 
simulated intestinal fluid (FaSSIF) (pH 6.5) and Fed state simulated intestinal fluid 
(FeSSIF) (pH 5) respectively. The dissolution fluids were prepared based on protocol 
given by Jogia et al., 2014 (Jogia et al., 2014) and Marques et al., 2004 (Marques, 2004). 
The composition of FaSSIF and FeSSIF was outlined in Table 19 and Table 20 
respectively. It resulted in negligible drug release in both intestinal conditions (Fig. 
34A), as the pH was not enough for polymer solubilization and hence there was no 
release of drug observed. Fig. 34B and Fig. 34C revealed that drug filaments were not 
solubilized at the end of dissolution. All the dissolution experiments were carried out 
in triplicate (n=3). 
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Table 19: Composition of Fasted state simulated intestinal fluid 
     (Adapted from Jogia et al., 2014) and Marques et al., 2004) 
 
 
 
 
Ingredient 
 
FaSSIF 
 
Sodium taurocholate 
 
3mM 
 
Lecithin 
 
0.75mM 
 
NaOH (Pellets) 
 
0.174g 
 
NaH2PO4.H2O 
 
1.977g 
 
NaCl 
 
3.093g 
 
Purified water q.s 
 
to 500 mL 
 
pH 
 
6.5 
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Table 20: Composition of Fed state simulated intestinal fluid 
(Adapted from Jogia et al., 2014 and Marques et al., 2004) 
 
 
 
 
 
Ingredient 
 
FeSSIF 
 
Sodium taurocholate 
 
15mM 
 
Lecithin 
 
3.75mM 
 
NaOH (Pellets) 
 
4.04g 
 
Glacial Acetic acid 
 
8.65g 
 
NaCl 
 
11.874g 
 
Purified water q.s 
 
to 1000 mL 
 
pH 
 
5.0 
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Fig. 34. A) In vitro dissolution of Single unit SJU tablet (n=3) in 500 mL of FaSSIF 
and FeSSIF respectively. B) Dissolution Jar of FaSSIF pH 6.5 C) Dissolution Jar of 
FeSSIF pH 5. 
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In vitro step dissolution of single unit SJU tablet (n=3) was carried out as per 
Solanki et al., 2018 (Solanki et al., 2019). Initial two hours the dissolution was carried 
out at pH 1.6, after two hours the pH was adjusted to 6.8 followed by collecting the 
samples up to additional 5 hours. The results showed that >90% of drug release was 
observed in the initial 2 hours. After the pH shift, only 15% of drug was present in the 
dissolution jar (Fig. 35A). No traces of filaments were observed in dissolution vessel 
at the end of initial 2 hours (Fig. 35B). Yet, once the pH has been shifted then rapid 
precipitation of drug and polymer was noted (Fig. 35C). Our observation was in well 
accordance with the literature (Wei et al., 2016). 
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Fig. 35. A) In vitro step dissolution of Single unit SJU tablet (n=3) at pH 1.6 for 
initial 2 hours followed by additional 5 hours after changing pH to 6.8. B) Dissolution 
vessel at end of 2nd hour C) Dissolution vessel at 3rd hour (After pH shift to 6.8). 
Dissolution vessel at end of 2nd hour Dissolution vessel at 3rd hour 
A) 
B) C) 
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Pharmacologic effect of loperamide is attained primarily by binding 
peripherally as a µ-receptor agonist on the mesenteric plexi of enteric wall. To evaluate 
the significance of HME processing technique in resisting the drug release during multi 
dose oral ingestion. A comparative dissolution study was conducted at pH 6.8 for one 
hour. All the samples were tested in triplicate (n=3). Within this study amount of drug 
release was compared between 60 mg of pure API and crushed filaments (based on 
Eudragit® EPO) having equivalent amount of 60 mg of drug. Pure API was used in this 
study instead of marketed formulation Imodium® comprising lactose, cornstarch, talc, 
and magnesium stearate. Because the pharmacologic effect is purely dependent on 
active form of drug available at the site of action. At the end of dissolution, a maximum 
of 18%±0.5 and 3.5%±0.5 was released from pure API and filaments respectively as 
shown in Fig. 36. The lower drug release from filaments can be attributed to its 
insolubility at pH 6.8 as Eudragit® EPO is not soluble at pH>5. This test was to prove 
that HME was imperative in preparation of LPH ADF which aids in producing 
molecular dispersion of drug within carrier polymer. Hence during dissolution, it was 
very essential for the initial solubilization of carrier polymer for the release of drug. 
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Fig. 36. Amount of drug released (~mg) at pH 6.8 during one hour between 
Pure API (60 mg) and Crushed filament with an equivalent amount of 60 mg (n=3). 
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Eudragit® EPO is a copolymer based on dimethylaminoethyl methacrylate, 
butyl methacrylate, and methyl methacrylate (2:1:1). Eudragit® EPO is soluble in a pH 
range of 1-4 and no reported solubility was found above pH 5(Huang et al., 2015). 
Eudragit® EPO is an amorphous polymer and cationic in nature. Literature indicated its 
application in enhancement of solubility of poorly soluble drugs (Saal et al., 2017). 
LPH reported to have a very low solubility (BCS class IV drug). During extrusion of 
LPH with Eudragit® EPO (low Tg 52
oC), it required a modified screw design (low shear 
type) to obtain drug loaded filaments. Subsequently, another gastric soluble polymer 
Kollicoat® Smartseal 100P (novel functional polymer from BASF) was investigated. It 
is a cationic polymer based on methyl methacrylate and diethylaminoethyl 
methacrylate copolymer. Kollicoat® Smartseal 100P is reported to be soluble at pH<5 
and insoluble at neutral pH (BASF, 2019). It’s a reverse enteric polymer used for taste 
masking and moisture protection. Similar to Eudragit® EPO low shear screw design was 
utilized for extrusion with Kollicoat® Smartseal 100P (low Tg 50oC). 
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In single unit dissolution of SJU1 and SJU2, the pH remained constant (~1.6) 
during dissolution. pH of medium was found to be unaltered by the presence of 100 mg 
of L-arginine per tablet. SJU1 was able to provide complete drug release compared to 
SJU2, which exhibited a slower release. Cationic polymeric backbone was able to 
solubilize quickly, thus getting LPH faster into solution in case of Eudragit® EPO (LPH 
was solubilized within polymer). Hence, SJU1 appears to provide rapid release on par 
with commercial product Imodium®. Despite having similar cationic polymeric 
backbone in Kollicoat® Smartseal 100P, interestingly SJU2 was able to achieve only a 
release of 50% in 45 minutes. Kollicoat® Smartseal 100P has diethyl group instead of 
dimethyl group in Eudragit® EPO, moreover Kollicoat® Smartseal 100P is more 
lipophilic in nature. Slower dissolution of Kollicoat® Smartseal 100P is attributed to i) 
diethyl group which is bulkier and more hydrophobic than dimethyl group ii) more 
lipophilic nature. Thereafter, in multi-unit dissolution, the rise in pH was noted to be 
8.67. Hence, the tablets SJU1 and SJU2 prepared using SJU technology were remained 
undissolved in dissolution vessels. It was obvious that cationic polymeric backbone 
found to be insoluble in higher pH. Because of this phenomenon, the drug release from 
SJU1 and SJU2 was found to be negligible (<1mg) throughout dissolution. At the same 
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time, Imodium® (comprising Lactose, cornstarch, talc, and magnesium stearate) 
showed almost complete release of drug. 
USFDA made an announcement on June 7th, 2016 to encourage a safer use of 
Imodium® (USFDA, 2018b). High doses of oral ingestion of Imodium® (poor man’s 
methadone) will lead adverse cardiac events. Accordingly, to confront the growth of 
opioid agonist drugs like Imodium®, we developed SJU technology approach. LPH 
loaded filaments of an acid soluble polymer - Eudragit® EPO was prepared using hot 
melt extrusion. Filaments were crushed and converted into a tablet containing 100 mg 
L-arginine. In single unit dissolution Imodium® and SJU1exhibited >85% of release in 
15 minutes with no presence of filaments observed in SJU1 dissolution jar. In multi- 
unit dissolution SJU1 and SJU2 demonstrated negligible release contrary Imodium® 
which exhibited >90% of release in 30 minutes. The success of our technology was 
exemplified by SJU1 that fulfilled the purpose of serving immediate release in single 
unit dissolution in addition to resisting the drug release in multi-unit dissolution. 
According to previous literature, abuser consumes 30 or higher tablets to get euphoria. 
We designed SJU1 tablets to deter the abuse in 15 tablets itself. In present work L- 
arginine a basic amino acid was employed throughout the study. It will be interesting 
to evaluate the other basic amino acids like lysine, histidine for similar application. 
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           6. Limitations 
Based on the USFDA an abuse deterrent formulation is not abuse proof or tamper 
resistant. The main objective at end is to deliver the drug to the patient. Hence there 
might be abuse of these products as well. Therefore, in present work. 
   Although majority of studies suggested by the USFDA were performed, few of 
the elements such as large volume extraction, heating-cooling cycle, and 
insufflation characterizations were not carried out due to limited scope and 
resource constrain. 
   Drug extraction from crushed egglets was not carried out. The drug extraction 
may be high from grounded egglets. 
   Multi tablet (egglet) solvent extraction may be possible and can be abused 
through IV route. 
   SJU tablet containing loperamide should be administered on an empty stomach 
to achieve immediate release for diarrheic patients. 
   Multi dose oral ingestion of SJU tablets may be possible with co-administration 
of apple cider vinegar (pH 2-3). 
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            7. Summary 
 
Abuse Deterrent Immediate Release Egg-Shaped Tablet Using 3D Printing 
Technology: Quality by Design to Optimize Drug Release and Extraction. 
As per our published work (Nukala et al., 2019b) 
 
 
An egg-shaped immediate release abuse deterrent formulation (egglet) was 
successfully developed using a fused deposition modeling (FDM) 3D printing 
technology and hot melt extrusion. 
PVA (Poly vinyl Alcohol) with 10% w/w sorbitol was found be the most 
suitable material for the preparation of crush and drug extraction resistant egg- 
shaped tablets (egglets). 
   Optimized egglets passed most tests described in the USFDA guidance for abuse 
deterrent opioids. Hardness (> 500 N) and physical manipulation (80% of 
particles more than > 1 mm size) confirmed the snort-resistant potential of 
egglets. 
   Egglets prepared using polymeric filaments of 15% w/w drug load and 45% 
infill density in small dimension (X-6.00mm: Y-4.4mm: Z-3.3 mm) were 
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meeting the QTPP—D85 < 30 min and percentage drug extraction in small 
volume of water < 15%. 
The optimized response models for dependent variables also correlated well 
with the data generated, confirming its validity. 
Thus, hot melt extrusion coupled with FDM 3D printing offers a platform for 
the preparation of dosage forms of opioids with an abuse deterrent property. 
Development of Multi-dose Oral Abuse Deterrent Formulation of 
Loperamide Using HME. 
As per our published work (Nukala et al., 2019a). 
 
Modern day abusers have been actively moving towards easily accessible OTC 
drugs like loperamide for attaining a ‘high’. To deter the administration of LPH 
in toxic and life-threatening conditions, the present study reports the successful 
development of a formulation for multi-dose oral abuse. 
Molecular dispersion of LPH in gastric soluble polymers (Eudragit® EPO and 
Kollicoat® Smartseal 100P) was achieved with hot melt extrusion. 
A combination of these filaments with a free base like L-arginine proved to be 
 
useful for deterring multi dose oral drug abuse. 
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Drug release from SJU1 (Eudragit® EPO based) tablets and Imodium® 
(marketed formulation of Loperamide) had a similar dissolution profile for 
single unit dissolution. Most importantly, SJU1 tablets exhibited minimal drug 
release in multi-unit dissolution due to increase in pH to 8, where Eudragit® 
EPO is insoluble. 
Hence, SJU formulation technology (LPH loaded Eudragit® EPO filament and 
L-arginine) could be an ideal, safe and promising technology to deter multi- 
dose oral ingestion abuse for loperamide. 
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